4th European Conference on Schizophrenia Research
Together for better treatment and care

Joint thematic congress of the European Scientific Association on Schizophrenia and other Psychoses (ESAS), the Competence Network on Schizophrenia (CNS), the European Psychiatric Association (EPA), and German Association for Psychiatry, Psycho-therapy and Psychosomatics (DGPPN)

26 – 28 September 2013
Berlin, Germany

in cooperation with

World Psychiatric Association (WPA)
and its Section on Schizophrenia

Final Programme

accredited by the European Council for Continuing Education (EACCME) with 16 CME credits

www.schizophrenianet.eu
# TABLE OF CONTENT

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Address</td>
<td>3</td>
</tr>
<tr>
<td>Conference Organisation</td>
<td>5</td>
</tr>
<tr>
<td>Conference Information</td>
<td>6</td>
</tr>
<tr>
<td>Format Descriptions / CME Credits</td>
<td>8</td>
</tr>
<tr>
<td>Opening Ceremony and Welcome Reception</td>
<td>10</td>
</tr>
<tr>
<td>Overview Scientific Programme</td>
<td>11</td>
</tr>
<tr>
<td>Scientific Programme</td>
<td></td>
</tr>
<tr>
<td>Thursday, 26 September</td>
<td>14</td>
</tr>
<tr>
<td>Friday, 27 September</td>
<td>24</td>
</tr>
<tr>
<td>Saturday, 28 September</td>
<td>40</td>
</tr>
<tr>
<td>Floorplan</td>
<td>50</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>51</td>
</tr>
<tr>
<td>Index Chairpersons, Authors and Presenters</td>
<td>52</td>
</tr>
</tbody>
</table>
Dear Colleagues,

In recent years a growing body of cutting-edge schizophrenia research was performed and new evidence was generated with regard to aetiology, symptomatology, treatment and care of schizophrenia. Treatment research on new pharmacological targets and novel mechanisms of action demonstrated encouraging efficacy across a range of symptoms allowing for a better and personalised treatment. New imaging techniques were developed to gain new insights in the pathophysiology of this disorder. Some recent findings may help to diagnose schizophrenia earlier in the course and to predict treatment response. Yet we are still far away from understanding the underlying causes and complexity of schizophrenia corresponding to heterogeneous patient needs. Publication of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) earlier this year has led to an intense and controversial discussion beyond the psychiatric community becoming a matter of public interest and media coverage.

The scientific programme of the European Conference on Schizophrenia Research (ECSR) critically discusses recent scientific advances, deals with current controversies, and updates the scientific knowledge about schizophrenia and translate it into clinical practice. The need to have a forum for scientific exchange and to address clinical challenges encouraged, in 2007, the Competence Network on Schizophrenia to initiate this biennial European schizophrenia congress which will be held for the fourth time.

According to this year’s motto “Together for better treatment and care”, the scientific programme of the ECSR provides a comprehensive overview on recent research projects and developments in schizophrenia treatment and documents the broad range of topics to be presented in plenary lectures, (prearranged and submitted) symposia, workshops, oral presentations and poster sessions. Treatment of negative symptoms, deficits in social cognition, non-adherence, and the promotion and implementation of evidence-based strategies to ensure standards of care as well as basic research topics will be addressed by high quality contributions from acknowledged experts, young scientists, and clinicians.
As in previous years, the co-organising psychiatric associations and their respective schizophrenia sections play an important role in this joint thematic conference. On occasion of the third ECSR the European Scientific Association on Schizophrenia and other Psychoses (ESAS) took over the responsibility to organise future ECSR. Yet, the tasks of ESAS are certainly not limited to organising this conference; further tasks may be the identification of emerging issues for schizophrenia research and, as a consequence, outlining a research agenda and initiation of collaborations and networking activities.

On behalf of the Scientific Committee and the organisers, I cordially welcome you at the 4th European Schizophrenia Research Conference and thank you for your attendance. I wish all of us inspiring days.

Sincerely yours,

Wolfgang Gaebel
Congress President
President European Scientific Association
on Schizophrenia and other Psychoses
Speaker of the Competence Network on Schizophrenia
ORGANISERS

European Scientific Association on Schizophrenia and other Psychoses (ESAS)

Competence Network on Schizophrenia (CNS)

European Psychiatric Association (EPA) and its Section on Schizophrenia

German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)

PROFESSIONAL CONFERENCE ORGANISER
Hanser & Co GmbH
Postfach 12 21
22882 Barsbüttel, Germany
Phone: +49 – 40 – 670 88 20
Fax: +49 – 40 – 670 32 83
Email: schizophrenia@cpo-hanser.de

SCIENTIFIC PROGRAMME COMMITTEE
Wolfgang Gaebel, Germany
Congress President

Georg Awad, Canada
Finn Bengtsson, Sweden
Dinesh Bhugra, UK
Gerd Buchkremer, Germany
George Christodoulou, Greece
Peter Falkai, Germany
Silvana Galderisi, Italy
Wagner F. Gattaz, Brazil
Birte Glenthoj, Denmark
Philippe Gorwood, France
Heinz Häfner, Germany
Cyril Höschl, Czech Republic
Joachim Klosterkötter, Germany
Valery Krasnov, Russia
Shôn Lewis, UK
Jan Libiger, Czech Republic
Wolfgang Maier, Germany
Mario Maj, Italy
Stephen Marder, USA
Patrick McGorry, Australia
Hans-Jürgen Möller, Germany
Merete Nordentoft, Denmark
Michael Owen, UK
Victor Peralta, Spain
Wulf Rössler, Switzerland
Pedro Ruiz, USA
Bernard Sabbe, Belgium
Norman Sartorius, Switzerland
Frank Schneider, Germany
Wolfgang Wölwer, Germany
Til Wykes, UK

LOCAL ORGANISER
PsychoseNetz e.V.
Wolfgang Gaebel, Wolfgang Wölwer,
Viktoria Toeller
c/o Department of Psychiatry
and Psychotherapy
Heinrich-Heine-University Düsseldorf
LVR Clinic Center
Bergische Landstraße 2
40629 Düsseldorf, Germany

SCIENTIFIC SECRETARIAT
European Scientific Association on Schizophrenia and other Psychoses (ESAS) e.V.
Wolfgang Gaebel, Wolfgang Wölwer,
Viktoria Toeller
c/o Department of Psychiatry and Psychotherapy
Heinrich-Heine-University Düsseldorf, Germany
CONFERENCE INFORMATION

CONFERENCE VENUE
Urania Berlin e.V.
An der Urania 17
10787 Berlin, Germany
www.urania.de

CONFERENCE REGISTRATION COUNTER
All conference material and documentation are available at the conference registration counter located in the foyer on the ground floor of the Urania.

OPENING HOURS
Thursday, 26 Sept. 2013 08.00 – 18.00 h
Friday, 27 Sept. 2013 08.00 – 19.45 h
Saturday, 28 Sept. 2013 08.00 – 16.00 h

During these opening hours the conference counter can be reached at:
Phone: +49 – 30 – 2100 81 63

REGISTRATION FEE

ON-SITE REGISTRATION
Members of ESAS, CNS, EPA, DGPPN, WPA  EUR 490,00
Non-members  EUR 540,00
Trainees *  EUR 440,00

* Non-tenured junior scientists or clinical residents in training under 35 years (Trainee status must be confirmed by a certificate in writing by head of department and copy of passport).

ABSTRACT BOOK
All accepted abstracts are published in an abstract book as a supplement of the European Archives of Psychiatry and Clinical Neurosciences (EAPCN). The abstract book will be handed out together with the conference documentation at the registration counter.

NAME BADGES
Participants are kindly requested to wear their name badge at all times during the conference including the Opening Ceremony and Welcome Reception.

CONFERENCE LANGUAGE
The conference language is English. Simultaneous translation will not be provided.

PROGRAMME CHANGES
The organisers cannot assume liability for any changes in the conference programme due to external or unforeseen circumstances.

CERTIFICATE OF ATTENDANCE
A certificate of attendance will be handed out upon demand at the registration counter.

MEDIA CHECK
The Media Check is located in hall Keppler on the first floor of the Urania. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before their session but at the latest 90 minutes prior to the presentation. The presentation will be transferred to a special conference notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook.

OPENING HOURS
Thursday, 26 Sept. 2013 08.00 – 18.00 h
Friday, 27 Sept. 2013 08.00 – 19.00 h
Saturday, 28 Sept. 2013 08.00 – 15.00 h
The poster exhibition is located in the foyers on the ground floor of the Urania. Posters will be on display for the entire time of the conference. They will be sorted by topics and will be numbered within those topics. The poster exhibition is open to all registered delegates, daily guided poster tours will take place chaired by senior scientists:

**Thursday, 26 Sept. 2013**
Guided Poster Tours P-01 – P-04: 13.30 – 14.30 h

**Friday, 27 Sept. 2013**
Guided Poster Tours P-05 – P-09: 13.30 – 14.30 h

**Saturday, 28 Sept. 2013**
Guided Poster Tours P-10 – P-13: 13.30 – 14.30 h

Interested participants can meet the authors for discussions of their poster presentation during the time of the poster tour.

**Set-up and dismantling times for posters**
**Set-up:**
Thursday, 26 Sept. 2013: 08.00 – 10.00 h

**Dismantling:**
Saturday, 28 Sept. 2013: 16.00 – 17.00 h

Posters which have not been removed within the indicated dismantling time will be disposed.

**COFFEE BREAKS**
Coffee, tea and mineral water will be served free of charge to all registered delegates during the morning and afternoon coffee breaks from Thursday, 26 September to Saturday, 28 September 2013. Coffee bar stations are located on the first floor and in the foyer of the ground floor next to the poster exhibition.

**LUNCH AND RESTAURANTS**
A lunch snack will be served to all registered delegates during the lunch breaks from Thursday, 26 September to Saturday, 28 September 2013 in the foyer of the ground floor next to the poster exhibition and on the first level. The conference venue further provides a restaurant on the first floor where snacks and food are available on cash basis.

**MOBILE PHONES**
Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions in the meeting rooms.

**INSURANCE**
The conference fee does not include insurance. All participants are advised to arrange for their own insurance. Health and accident insurance is recommended and has to be purchased in your country of residence.

**HOW TO GET TO THE URANIA:**
**By plane**
The congress venue Urania is just 8 km from Tegel airport and 22 km from Schönefeld airport.

**By train**
Centrally located within the heart of Berlin close to Tiergarten and Lützowplatz, the Urania is just 5 km from Berlin’s main train station, and only a few minutes by car or taxi.

**By car**
Access to Berlin via the motorways A111, A113 or A115 with direction to Tiergarten / Lützowplatz. The Urania is located in the street “At the Urania”, crossed by the Kurfürstenstrasse.

**By public transportation**
The Urania is well connected within the public transport network via U-Bahn lines 1, 2, 3 and 4 at the Wittenbergplatz and Nollendorfplatz U-Bahn stations, as well as via bus lines.

**PARKING**
The Urania provides 40 parking places free of charge in the courtyard.
The scientific programme will comprise the following formats:

**PLENARY LECTURES**
Invited lectures of 45 min each, covering current hot spots in schizophrenia research and given by leading European experts.

**SYMPOSIA**
Pre-arranged or submitted symposia of 90 min each, including four presentations and 15 min time for discussion covering major topics of the conference. Both symposia with a clear scientific focus and those with a clear clinical focus will be included.

**WORKSHOPS**
Pre-arranged workshops allowing for detailed discussion on scientific topics in particular serving transnational collaboration within Europe. Participation is included in the registration fee. For W-01 and W-02 preliminary registration is required.

**ORAL PRESENTATION SESSIONS**
Submitted presentations grouped by topics into thematic oral sessions of 90 min, including six or seven papers each.

**POSTER SESSIONS**
Submitted presentations grouped by topics into thematic guided poster sessions.

---

**CME ACCREDITATION**
The ‘European Scientific Association on Schizophrenia and other Psychoses (ESAS)’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS).

www.uems.net.

The ‘4th European Conference on Schizophrenia Research (ECSR)’ is designated for a maximum of 16 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

---

Submit Your Abstract
Abstract Submission Deadline: 1 October 2013
Submit Your Abstract
Abstract Submission Deadline: 1 October 2013

22nd EUROPEAN CONGRESS OF PSYCHIATRY

Munich, Germany 1-4 March 2014

EUROPEAN PSYCHIATRY FOCUSING ON BODY AND MIND

www.epa-congress.org
OPENING AND WELCOME RECEPTION

THURSDAY, 26 SEPTEMBER 2013

Opening Ceremony

09.15 – 10.15 h

Humboldt Hall

- Presidential Address
  Professor Wolfgang Gaebel, Düsseldorf Germany
  Congress President, Chair of the European Scientific Association on Schizophrenia and other Psychoses (ESAS), Speaker of the Competence Network on Schizophrenia (CNS)

- Welcome Addresses
  Professor Danuta Wasserman, Stockholm, Sweden
  President of the European Psychiatric Association (EPA)

  Professor Wolfgang Maier, Bonn, Germany
  President of the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)

  Professor Tarek Okasha, Cairo, Egypt
  Secretary for Scientific Meetings of the World Psychiatric Association (WPA)

  Professor Andi Jayalangkara Tanra, Makassar, Indonesia
  President of the Asian College for Schizophrenia Research (ACSR)

- Aretaeus-Award Ceremony – Laureate 2013

Welcome Reception

19.00 – 20.00 h

Foyers

At the end of the scientific sessions participants are invited to join the Welcome Reception in the foyers of the first level of the Urania. Finger food and drinks will be provided.
<table>
<thead>
<tr>
<th>Room</th>
<th>Humboldt</th>
<th>Kleist</th>
<th>Loft A</th>
<th>Einstein</th>
<th>Loft C</th>
<th>Foyer</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.15 – 10.15</td>
<td>Opening Ceremony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15 – 11.00</td>
<td>PL-01 Toward new approaches to classifying psychotic spectrum disorders: the NIMH Research Domain Criteria Project</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30 – 13.00</td>
<td>S-01 Beyond DSM-5 and ICD-11: how should psychotic disorders be conceptualized and diagnosed in the future?</td>
<td>S-02 Preventive outpatient treatment approaches for schizophrenia–associated violence and delinquency</td>
<td>S-03 Apathy in schizophrenia – clinical, experimental and therapeutic approaches</td>
<td>S-04 The mild encephalitis hypothesis of schizophrenia updated: low level neuroinflammation, autoimmunity, volume transmission, treatment approaches</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00 – 14.30</td>
<td>Lunch Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30 – 14.30 h</td>
<td>Guided Poster Tours P-01 to P-04</td>
<td>P-01: Treatment (drug) 1</td>
<td>P-02: Neuropsychology 1</td>
<td>P-03: Comorbidity and psychopathology</td>
<td>P-04: Course and outcome</td>
<td></td>
</tr>
<tr>
<td>14.30 – 16.00</td>
<td>S-05 Approaches for predicting development of psychosis</td>
<td>S-06 The risks and benefits of antipsychotic polypharmacy: clinical relevance and development of evidence</td>
<td>S-07 Dimensional concepts of psychosis</td>
<td>O-01 Neurobiology</td>
<td>W-01: Part 1 How to write manuscripts for publication in English language scientific journals</td>
<td></td>
</tr>
<tr>
<td>16.30 – 18.00</td>
<td>S-08 Biological pathways to psychosis: the role of stress</td>
<td>S-09 Suicide prevention in schizophrenia</td>
<td>S-10 Eye movement research: a window to cognitive impairments in schizophrenia?</td>
<td>S-11 Microglia in schizophrenia</td>
<td>W-01: Part 2 How to write manuscripts for publication in English language scientific journals</td>
<td></td>
</tr>
<tr>
<td>18.15 – 19.00</td>
<td>PL-02 Shifting paradigms for therapeutic discovery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00 – 20.00</td>
<td>Welcome Reception</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room</td>
<td>Time</td>
<td>Humboldt</td>
<td>Kleist</td>
<td>Loft A</td>
<td>Einstein</td>
<td>Loft C</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
<td>----------</td>
<td>--------</td>
<td>--------</td>
<td>----------</td>
<td>--------</td>
</tr>
<tr>
<td></td>
<td>08.30 – 10.00</td>
<td>S-12</td>
<td>S-13</td>
<td>S-14</td>
<td>O-02</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Negative symptoms – impact and therapeutic options</td>
<td>Progression in brain tissue loss, antipsychotic medication, cognition and outcomes in schizophrenia – the Northern Finland 1966 Birth Cohort Study</td>
<td>Translational genetics for psychiatric illnesses</td>
<td>Neuropsychology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10.30 – 12.00</td>
<td>S-15</td>
<td>S-16</td>
<td>S-17</td>
<td>O-03</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>The future of psychopathology in the light of current neuroscience</td>
<td>New approaches to cognitive behavior therapy for psychosis</td>
<td>Epigenetic dysregulation in schizophrenia</td>
<td>Functional Neuroimaging</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12.15 – 13.00</td>
<td>PL-03</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Structure and function of the human brain at the level of receptors and neural systems: a basis for psychiatric research</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00 – 14.30</td>
<td>Lunch Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13.30 – 14.30 h</td>
<td>Guided Poster Tours P-05 to P-09</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P-05: Neurobiology and genetics</td>
<td>P-06: Functional neuroimaging</td>
<td>P-07: Research methods and health service research</td>
<td>P-08: Neuropsychology</td>
<td>P-09: Treatment 2</td>
</tr>
<tr>
<td></td>
<td>14.30 – 16.00</td>
<td>S-22</td>
<td>S-19</td>
<td>S-20</td>
<td>S-21</td>
<td>W-02</td>
</tr>
<tr>
<td></td>
<td></td>
<td>From structure to functioning: neurobiological candidates for the prediction of psychoses</td>
<td>Should continuous antipsychotic medication be recommended after first episode psychosis?</td>
<td>The role of neuroinflammation in schizophrenia</td>
<td>Experimental psychopathology of psychosis</td>
<td>How to apply for EU-funding</td>
</tr>
<tr>
<td></td>
<td>16.30 – 18.00</td>
<td>S-18</td>
<td>S-23</td>
<td>S-24</td>
<td>O-04</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Perspectives in schizophrenia research: emerging research issues</td>
<td>Implementation of early intervention services for young people with first episode psychosis: rationale, evidence and practical experiences from Europe</td>
<td>Studies using structural and functional neuroimaging to advance understanding of schizophrenia</td>
<td>Comorbidity</td>
<td></td>
</tr>
<tr>
<td>18.15 – 19.45</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>19.15 – 19.45</td>
<td>S-25</td>
<td>S-26</td>
<td>S-27</td>
<td>O-05</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nosology in the schizophrenic psychoses: new insight from functional neuroimaging and genetics</td>
<td>The consequences of childhood trauma in psychotic disorders</td>
<td>Progress in neuropsychological post-mortem findings in schizophrenia</td>
<td>Course and outcome</td>
<td></td>
</tr>
</tbody>
</table>
## Saturday, 28 September 2013 – OVERVIEW

<table>
<thead>
<tr>
<th>Room</th>
<th>Humboldt</th>
<th>Kleist</th>
<th>Loft A</th>
<th>Einstein</th>
<th>Loft C</th>
<th>Foyer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Time</strong></td>
<td><strong>Overview</strong></td>
<td><strong>Time</strong></td>
<td><strong>Overview</strong></td>
<td><strong>Time</strong></td>
<td><strong>Overview</strong></td>
<td><strong>Overview</strong></td>
</tr>
<tr>
<td><strong>08.30 – 10.00</strong></td>
<td><strong>S-28</strong> The high risk state for psychosis</td>
<td><strong>S-29</strong> The role of oligodendrocytes in schizophrenia: disease-inherent versus treatment-induced abnormalities</td>
<td><strong>S-30</strong> Oscillations and synchrony in cortical networks in schizophrenia</td>
<td><strong>O-06</strong> Treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10.30 – 12.00</strong></td>
<td><strong>S-31</strong> Indicated prevention of psychosis</td>
<td><strong>W-03</strong> International perspectives of quality of care and integration of persons with schizophrenia</td>
<td><strong>S-32</strong> Single symptom approaches in schizophrenia: neuronal correlates of auditory hallucinations and language related symptoms</td>
<td><strong>S-33</strong> The schizophrenia motor dimension: clinical relevance and neurobiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12.15 – 13.00</strong></td>
<td><strong>PL-04</strong> Twenty years of early intervention in psychosis: how critical is the critical period hypothesis?</td>
<td><strong>Lunch Break</strong></td>
<td><strong>Guided Poster Tours P-10 to P-13</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>13.00 – 14.30</strong></td>
<td><strong>S-34</strong> Obsessive-compulsive symptoms in schizophrenia</td>
<td><strong>S-35</strong> Psychological treatments for people with schizophrenia</td>
<td><strong>S-36</strong> Animal models of schizophrenia facing the complexity of genotype, environmental factors and phenotype</td>
<td><strong>O-07</strong> Structural neuroimaging</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>14.30 – 16.00</strong></td>
<td><strong>S-37</strong> Psychopathology of the first and second order in schizophrenia</td>
<td><strong>S-38</strong> Cognitive remediation therapies for schizophrenic patients</td>
<td><strong>S-39</strong> Family interventions in schizophrenia</td>
<td><strong>O-08</strong> Structural neuroimaging</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Registration Counter**
Opening Hours: 08.00 – 16.00

---

**Legend**
- **PL-Plenary Lecture**
- **S-Symposium**
- **W-Workshop**
- **O-Oral Presentation**
- **P-Poster**
PL-01  PLENARY LECTURES
10.15 – 11.00 h  Humboldt Hall
Toward new approaches to classifying psychotic spectrum disorders: the NIMH Research Domain Criteria Project
Chair: S. Galderisi, Naples, Italy

S-01  SYMPOSIA
11.30 – 13.00 h  Humboldt Hall
Beyond DSM-5 and ICD-11: how should psychotic disorders be conceptualized and diagnosed in the future?
Chairs: A. Heinz, Berlin, Germany
        W. Gaebel, Düsseldorf, Germany

S-01-001  Functional impairment – a mandatory criterion for mental disorders?
W. Gaebel, Düsseldorf, Germany

S-01-002  How to distinguish between symptoms of a mental disease and impairments of (social) functions
A. Heinz, Berlin, Germany
        E. Friedel

S-01-003  Are there specific symptoms that guide schizophrenia diagnosis?
S. Galderisi, Naples, Italy

S-01-004  Can key symptoms of schizophrenia be matched to brain systems?
W. Strik, Bern, Switzerland
        T. Dierks

S-02  SYMPOSIA
11.30 – 13.00 h  Kleist Hall
Preventive outpatient treatment approaches for schizophrenia-associated violence and delinquency
Chairs: C. Luckhaus, Düsseldorf, Germany
        S. Hodgins, Montreal, Canada

S-02-001  The multifactorial basis of violence in schizophrenia
S. Hodgins, Montreal, Canada

S-02-002  A psychoeducational intervention programme to reduce compulsory hospital readmission in the Canton of Zurich
B. Lay, Zurich, Switzerland
        T. Schönenberger, M. Bleiker, S. Lengler, C. Blank, W. Rössler

S-02-003  A preventive outpatient clinic for high-risk-of-violence patients in the region of Ansbach, Bavaria
J. Nitschke, Ansbach, Germany
        C. Luckhaus

S-02-004  A complex-therapeutic intervention programme for schizophrenia outpatients targeted at reducing violent offending and compulsory detention in Düsseldorf, North Rhine-Westphalia
C. Luckhaus, Düsseldorf, Germany
<table>
<thead>
<tr>
<th>S-03</th>
<th>SYMPOSIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30 – 13.00 h</td>
<td>Loft A</td>
</tr>
<tr>
<td>Apathy in schizophrenia – clinical, experimental and therapeutic approaches</td>
<td></td>
</tr>
<tr>
<td>Chairs: S. Kaiser, Zurich, Switzerland</td>
<td></td>
</tr>
<tr>
<td>A. Aleman, Groningen, The Netherlands</td>
<td></td>
</tr>
</tbody>
</table>

S-03-001
Apathy in first episode psychosis: similarities and differences to other brain disorders
A. Faerden, Oslo, Norway

S-03-002
Apathy as a disturbance of motivational and cognitive processes subserving goal-directed behavior
S. Kaiser, Zurich, Switzerland

S-03-003
Role of frontostriatal and frontoparietal networks in apathy
A. Aleman, Groningen, The Netherlands

S-03-004
Bilateral repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: findings from a double-blind randomized controlled trial
J. Dlabac-De Lange, Groningen, The Netherlands
L. Bais, A. Aleman, H. Knegtering

<table>
<thead>
<tr>
<th>S-04</th>
<th>SYMPOSIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30 – 13.00 h</td>
<td>Einstein Hall</td>
</tr>
<tr>
<td>The mild encephalitis hypothesis of schizophrenia updated: low level neuroinflammation, autoimmunity, volume transmission, treatment approaches</td>
<td></td>
</tr>
<tr>
<td>Chairs: K. Bechter, Guenzburg, Germany</td>
<td></td>
</tr>
<tr>
<td>B. Lennox, Oxford, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

S-04-001
Antiinflammation and psychoimmunomodulation in schizophrenia
E. Weidinger, Munich, Germany
N. Müller

S-04-002
Autoimmunity to NMDA receptors in schizophrenia
B. Lennox, Oxford, United Kingdom

S-04-003
Volume transmission balancing wiring (e.g. synaptic) transmission
D. Borroto-Escuela, Stockholm, Sweden
K. Fuxe

S-04-004
The mild encephalitis hypothesis of schizophrenia updated
K. Bechter, Guenzburg, Germany
P-01-001  
Bupropion treatment in schizophrenia: Risks and benefits according to the current literature  
S. Englisch, Mannheim, Germany  
K. Morgen, A. Meyer-Lindenberg, M. Zink

P-01-002  
Mirtazapine treatment in schizophrenia: evidences derived from the current literature  
S. Englisch, Mannheim, Germany  
F. Afflerbach, M. Zink

P-01-003  
2-Bromoterguride – an antipsychotic drug?  
J. Brosda, Berlin, Germany  
R. Franke, H. Pertz, H. Fink

P-01-004  
Use of long acting antipsychotic injections in the maintenance treatment of chronic schizophrenia  
E. Gemma, Terrassa, Spain  
M. A. Gloria, R. Guillamat, M. Maria, A. M. Fargas

P-01-005  
Effect of first and second generation antipsychotics on face affect expression in German and Chilean patients with schizophrenia  
V. W. Larach, Santiago, Chile  
A. Gazmuir, L. F. Varela Espinoza, W. Wölwer, W. Gaebel

P-01-006  
Adverse metabolic effects associated with use of long acting antipsychotic injections in the maintenance treatment of chronic schizophrenia  
M. Gloria, Barcelona, Spain  
G. Español, V. Valles, M. Montoro, A. M. Fargas

P-01-008  
Descriptive analysis of schizophrenic patients in regular control in an atypical antipsychotic program in Chile  
A. Armijo, Santiago, Chile  
J. Villarroel, F. Valenzuela, D. Castillo, H. Silva

P-01-009  
Prediction of antipsychotic therapy results basing on GSTM1 gene polymorphism in schizophrenic patients with different admission rate  
V. Obiedkov, Minsk, Belarus  
O. Skugarevsky, I. Halayenka

P-01-010  
DTNB1, HSPs and TAAR6 variations influence schizophrenic phenotype and treatment response  
T.-Y. Jun, Seoul, Republic of Korea  
C.-U. Pae

P-01-011  
Neuroleptic malignant syndrome and swan neck deformity  
E. Neroutsos, Elefsina-Athens, Greece  
A. Graikiotis, J. Ntampos, M. Fiste, N. Lytra, E. Thermou
P-02 POSTER SESSIONS
13.30 – 14.30 h Foyer

Neuropsychology 1
Chair: M. Green, Sydney, Australia

P-02-001
Anticipation and recall of emotions in subclinical negative symptoms – an experimental study in a social context
M. Engel, Hamburg, Germany
T. M. Lincoln, A. Fritzsche

P-02-003
Different strategies of schizophrenia patients in the visual exploration of social stimuli
K. Drusch, Düsseldorf, Germany

P-02-004
Neurophysiological correlates of defective emotional processing in schizophrenic patients with chronic auditory hallucinations
E. Grasa, Barcelona, Spain

P-02-005
Neural underpinnings of inhibitory control in schizophrenia patients with a history of violence: a high-density electrical mapping study
G. Andrade, Bronx, New York, USA
J. Butler, M. Krakowski, J. Foxe, P. De Sanctis

P-02-006
Early sensory-perceptual contributions to emotional processing deficits in schizophrenia patients with a history of violent behavior
W. Ritter, New York, USA
P. De Sanctis, G. N. Andrade, J. S. Butler, M. I. Krakowski, J. J. Foxe

P-02-007
Affectively valenced stimuli modulate different processing stages of the inhibitory control circuit in schizophrenia patients with and without a history of violence
P. De Sanctis, New York, USA
J. J. Foxe, G. N. Andrade, P. Czobor, M. I. Krakowski

P-02-008
Metacognitive beliefs and thought control strategies in early psychosis
T. Østefjells, Oslo, Norway
R. Hagen, J. I. Røssberg

P-02-010
The integration of evidence is associated with neurocognitive capabilities in schizophrenia
S. Eifler, Mannheim, Germany

P-02-011
Interpersonal decentering in patients with schizophrenia
K. Hosakova, Bilovec, Czech Republic
M. Lecbych
**P-03 POSTER SESSIONS**

13.30 – 14.30 h  
Foyer

**Comorbidity and psychopathology**  
Chair: W. Strik, Bern, Switzerland

**P-03-001**  
Immigrants do not show a specific psychosis symptom profile using a cross-culturally validated model of the PANSS  
A. Berg, Oslo, Norway  

**P-03-002**  
Family factor of adaptation of patients with schizophrenic disorders  
E. Gutkevich, Tomsk, Russia  
O. Danilenko, M. Zinchuk, A. Semke

**P-03-003**  
Family assessment among patients with various mental disorders  
H. Sadek, Cairo, Egypt  
S. Rabei

**P-03-004**  
Clinical-dynamic characteristics of schizophrenia associated with somatic pathology  
V. Lebedeva, Tomsk, Russia  
A. Semke, E. Yurovskaya

**P-03-005**  
Alexithymia is associated with psychotic and hypomanic symptoms  
M. Joukamaa, Tampere, Finland  
S. Luutonen, R. K. Salokangas

**P-03-006**  
Megalomania in dementia paralytica  
I. Daey Ouwens, Venray, The Netherlands  
E. Lens, A. Ott, P. Koehler, W. Verhoeven

**P-03-007**  
Schizophrenia-like psychosis and concurrent Substance Abuse: descriptive analysis and phenomenological approach in a Colombian inpatient early phase rehabilitation program  
P. Zuleta, Bogotá, Colombia  
C. Rodríguez, G. Oviedo, F. Muñoz, J. Navarro

**P-03-008**  
Alcohol use in schizophrenic patients  
M. Del Carmen García Mahía, A Coruña, Spain  
E. Roman Fernandez, M. Vidal Millares

**P-03-010**  
Prevalence of risk factors in homicidal behavior in schizophrenic patients  
I. Aliko, Tirane, Albania  
A. Kazaferi
Thursday, 26 September 2013 – SCIENTIFIC PROGRAMME

**P-04 POSTER SESSIONS**

13.30 – 14.30 h Foyer

**Course and outcome**

*Chair: V. Larach, Santiago, Chile*

**P-04-001**

Duration of untreated psychosis in patients with a first episode psychosis in a high-income-versus a low- and middle income-region

*N. Mossaheb, Vienna, Austria

**P-04-002**

Characteristics of illnesses and their course within the „psychotic continuum“ – predictive value for current psychopathology, cognition and functional outcome

*J. Hallaschek, Halle, Germany
S. Watzke*

**P-04-003**

Metacognition and negative symptoms in first episode psychosis: cross-sectional and longitudinal findings

*A. Macbeth, Elgin, United Kingdom
H. McLeod, A. Gumley, M. Schwannauer, P. Lysaker, G. Dimaggio*

**P-04-004**

Comparative of adolescent and adult onset psychosis: one year follow up

*M. Dolz, Esplugues de Llobregat (BCN), Spain
J. Tor, J. Carlson, B. Sánchez, M. Pardo, D. Muñoz, A. Barajas, I. Baños, J. Usall, S. Ochoa*

**P-04-006**

Factors affecting health related quality of life in psychiatric inpatients during treatment

*G. Lyrakos, Nikaia, Greece
V. Spinaris, I. Spyropoylos*

**P-04-008**

High religiousness, less perspective-taking and social suffering distinguish stable schizophrenia patients

*R. Duñó, Sabadell, Spain
S. Díaz-Morán, A. Tobeña*

**P-04-010**

Schizophrenia with obsessive–compulsive disorder comorbidity – clinical and treatment particularities

*A. Ciobanu, Bucharest, Romania*
### S-05 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Topic</th>
<th>Organiser/Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 16.00 h</td>
<td>Humboldt Hall</td>
<td>Approaches for predicting development of psychosis</td>
<td>CNS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Organised by the Competence Network on Schizophrenia (CNS)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs: M. Marshall, Manchester, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Klosterkötter, Cologne, Germany</td>
<td></td>
</tr>
</tbody>
</table>

#### S-05-001
Prognostic and therapeutic validity of the Attenuated Psychosis Syndrome
P. Fusar-Poli, London, United Kingdom

#### S-05-002
The epidemiologic perspective of risk identification and psychosis prediction
I. Kelleher, Dublin, Ireland
A. Murtagh, C. Molloy, S. Roddy, M.C. Clark, M. Harley, M. Cannon

#### S-05-003
Predicting psychosis in clinical practice—outcome of patients seen in a NHS Prodrome Clinic
M. Marshall, Manchester, United Kingdom
C. Johnson, K. Neelam, R. Drake

#### S-05-004
How to improve the prediction of psychosis
S. Ruhrmann, Cologne, Germany

### S-06 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Topic</th>
<th>Organiser/Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 16.00 h</td>
<td>Kleist Hall</td>
<td>The risks and benefits of antipsychotic polypharmacy: clinical relevance and development of evidence</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs: J. Cordes, Düsseldorf, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>W. Fleischhacker, Innsbruck, Austria</td>
<td></td>
</tr>
</tbody>
</table>

#### S-06-001
Antipsychotic drug target occupancy in PET studies: lessons for combining antipsychotics?
G. Gründer, Aachen, Germany

#### S-06-002
When to switch or combine: time course for response in antipsychotic drug treatment
M. Jäger, Guenzburg, Germany

#### S-06-003
The development of multiple antipsychotic combination treatment in comparison between European countries – findings from the AMSP project
A. Konstantinidis, Vienna, Austria
J. Cordes, D. Degner, T. Schuhmann, S. Kasper

#### S-06-004
A RCT to assess the benefits of Olanzapine and Amisulpride combination treatment (COMBINE): design and methods
C. Schmidt-Kraepelin, Düsseldorf, Germany
### S-07 SYMPOSIA

**14.30 – 16.00 h**  
Loft A  
**Dimensional concepts of psychosis**  
*Chairs:* W. Strik, Bern, Switzerland  
A. Heinz, Berlin, Germany

**S-07-001**  
Dimensions of psychotic symptoms and brain physiology  
*W. Strik, Bern, Switzerland*  
*S. Walther, A. Wopfner, K. Stegmayer, D. Hubl, H. Horn, T. Dierks*

**S-07-002**  
Thought and language disorders in psychosis  
*T. Kircher, Marburg, Germany*

**S-07-003**  
Dysfunctions of the motor system in schizophrenia  
*S. Walther, Bern, Switzerland*

**S-07-004**  
The limbic system and positive symptoms of schizophrenia  
*A. Heinz, Berlin, Germany*

### O-01 ORAL PRESENTATIONS

**14.30 – 16.00 h**  
Einstein Hall  
**Neurobiology**  
*Chair:* A. Papassotriopoulos, Basel, Switzerland

**O-01-001**  
Deviations of levels of serum auto-antibodies (a-Ab) to the antigens of nervous tissue in patients with schizophrenia: confirmation of the mild encephalitis hypothesis  
*V. Orlova, Moscow, Russia*  
*I. Mikhailova, V. Minutko, N. Eliseeva, J. Kretova*

**O-01-002**  
Evaluation of a potential endophenotype marker in schizophrenia: a blunted niacin response  
*J. Yao, Pittsburgh, USA*  
*G. Dougherty, G. Haas, R. Condray, E. Messamore*

**O-01-003**  
The role of agmatine in pathogenesis of schizophrenia  
*T. Uzbay, Istanbul, Turkey*  
*H. Kayir*

**O-01-004**  
Reduced striatal adenosine A(2A) receptor levels define a molecular subgroup in schizophrenia  
*M. Barrachina, L’Hospitalet de Llobregat, Spain*  
*I. Villar-Menéndez, S. Diaz-Sanchez, M. Blanch, J. L. Albasanz, T. Pereira-Veiga, A. Monje, L. M. Planchat, I. Ferrer, M. Martin*

**O-01-005**  
Correlative multiscale volume microscopy study of white matter cell structures in post-mortem samples of human brain  
*V. Shklover, Skolkovo, Odintsovy District, Russia*  
*N. Uranova, V. Chepanov, A. Lavrenyuk, P. Kazanskiy*

**O-01-006**  
Impact of chronic nicotine treatment on Hippocampal Oscillatory Activity in a G72/30 transgenic mouse model for schizophrenia  
*A. Lundt, Bonn, Germany*  
Biological pathways to psychosis: the role of stress

Chairs: D. Nordholm, Copenhagen, Denmark  
S. Wood, Birmingham, United Kingdom

Pituitary volume, cortisol and stress in healthy controls, ultra high-risk subjects and first episode psychosis subjects

D. Nordholm, Copenhagen, Denmark  
E. Rostrup, L. Ronders, M. O. Nielsen, H. Emig-Norbak,  
V. Mondelli, P. Dazzan, M. Nordentoft, B. Glenthøj

The effect of stress and its biological mediators on the onset and clinical outcome of psychosis

V. Mondelli, London, United Kingdom

The effect of stress on cortical thickness, surface area and subcortical brain volume in first episode psychosis over the first 12 weeks of treatment

R. Reniers, Birmingham, United Kingdom

Effect of pre-exposure to chronic social stress on HPA axis and neurotoxicity in animal models of schizophrenia

D. Inta, Mannheim, Germany  
D. Filipovic, P. Gass

Epidemiology of suicide and attempted suicide in the population of schizophrenic patients

A. Schmidtke, Wuerzburg, Germany  
D. Wasserman, B. Pfuhlmann, M. Sarchiapone, J. Maloney

Psychotic symptoms as a risk marker for suicidal behaviour

I. Kelleher, Dublin, Ireland  
P. Corcoran, H. Keeley, J.T.W. Wigman, N. Devlin,  
H. Ramsay, C. Wasserman, V. Carli, M. Sarchiapone, C. Hoven, D. Wasserman, M. Cannon

Strategies and possibilities in suicide prevention

D. Wasserman, Stockholm, Sweden

Challenges in clinical practice: predicting, treating and rehabilitating suicidal schizophrenia patients

S. Galderisi, Naples, Italy

Shifting paradigms for therapeutic discovery

W. T. Carpenter Jr., Baltimore, USA
### S-10 SYMPOSIA

**16.30 – 18.00 h**  
**Loft A**

**Eye movement research: a window to cognitive impairments in schizophrenia?**

*Chairs: W. Wölwer, Düsseldorf, Germany  
M. Boucart, Lille, France*

#### S-10-001

**Independence of smooth pursuit and visual scanpaths and a model of eye movement dysfunction in major mental illnesses**

*P. Benson, Aberdeen, United Kingdom  
S. A. Beedie, E. Nouzová, D. St. Clair*

#### S-10-002

**The relationship between visual exploration and action processing in schizophrenia**

*M. Boucart, Lille, France*

#### S-10-003

**Gaze behavior in early states of psychosis**

*S. Ruhrmann, Cologne, Germany  
A. Nikolaides, S. Miess, R. Müller, J. Klosterkötter*

#### S-10-004

**Concurrent assessment of eye movements and EEG in schizophrenia**

*S. Stroth, Düsseldorf, Germany  
K. Drusch, D. Kamp, W. Wölwer*

### S-11 SYMPOSIA

**16.30 – 18.00 h**  
**Einstein Hall**

**Microglia in schizophrenia**

*Chairs: S. Wolf, Berlin, Germany  
P. Falkai, Munich, Germany*

#### S-11-001

**HLA-DR+ microglia are increased in paranoid schizophrenia versus residual schizophrenia: evidence from human postmortem studies**

*J. Steiner, Magdeburg, Germany  
S. Busse, H.-G. Bernstein, B. Bogerts*

#### S-11-002

**Immunohistochemical investigations of microglia in schizophrenia**

*A. Schmitt, Munich, Germany  
T. Bayer, P. Falkai*

#### S-11-003

**Microglia properties in schizophrenia**

*A. Friebe, Bochum, Germany  
G. Juckel*

#### S-11-004

**Epigenetic changes in microglia derived from an animal model for schizophrenia**

*S. Wolf, Berlin, Germany  
D. Mattei*
### S-12 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 10.00 h</td>
<td>Humboldt Hall</td>
<td>Negative symptoms – impact and therapeutic options</td>
<td>N. Sartorius, Geneva, Switzerland</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>W. Gaebel, Düsseldorf, Germany</td>
</tr>
</tbody>
</table>

#### S-12-001
Negative symptoms in schizophrenia: prevalence and impact on functional outcome  
S. Galderisi, Naples, Italy

#### S-12-002
Negative symptoms, culture and the stigma of schizophrenia  
N. Sartorius, Geneva, Switzerland

#### S-12-003
Current therapeutic options and unmet needs in treating negative symptoms in schizophrenia  
W. Gaebel, Düsseldorf, Germany

#### S-12-004
Future prospects in the treatment of schizophrenia negative symptoms  
D. Bugarski-Kirola, Switzerland

### S-13 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 10.00 h</td>
<td>Kleist Hall</td>
<td>Progression in brain tissue loss, antipsychotic medication, cognition and outcomes in schizophrenia – the Northern Finland 1966 Birth Cohort Study</td>
<td>J. Miettunen, Oulu, Finland</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M. Isohanni, Oulu, Finland</td>
</tr>
</tbody>
</table>

#### S-13-001
Outcomes of schizophrenia from a lifespan perspective – the Northern Finland 1966 Birth Cohort Study  
M. Isohanni, Oulu, Finland

D. Cowling, P. Juola, J. Moilanen, A. Husa, M. Penttilä, S. Huhtaniska, J. Veijola, J. Miettunen, E. Jääskeläinen

#### S-13-002
Antipsychotic medication and longitudinal changes in brain volume in schizophrenia: meta-analysis and results from the Northern Finland 1966 Birth Cohort Study  
J. Miettunen, Oulu, Finland  
S. Huhtaniska, N. Hirvonen, J. Remes, G. Murray, J. Veijola, M. Isohanni, E. Jääskeläinen

#### S-13-003
Longitudinal association between antipsychotic medication and change of cognition in schizophrenia – the Northern Finland 1966 Birth Cohort Study  
A. Husa, Oulu, Finland  

#### S-13-004
Duration of untreated psychosis and outcomes and brain volume loss in schizophrenia – the Northern Finland 1966 Birth Cohort Study  
M. Penttilä, Oulu, Finland
S-14 SYMPOSIA
08.30 – 10.00 h Loft A
Translational genetics for psychiatric illnesses
Organised by the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)
Chairs: W. Maier, Bonn, Germany
T. Schulze, Göttingen, Germany

S-14-001
Genetic mouse models of relevance to schizophrenia: converging neurobiological mechanisms?
J. A. Pratt, Glasgow, United Kingdom

S-14-002
The path to translating genetics into clinical psychiatry: a realistic assessment
T. Schulze, Göttingen, Germany

S-14-003
Rat models for cognition and cognitive deficits
D. Bartsch, Mannheim, Germany

S-14-004
The genetic basis of human memory and its relevance for neuropsychiatric disorders
A. Papassotiropoulos, Basel, Switzerland

O-02 ORAL PRESENTATIONS
08.30 – 10.00 h Einstein Hall
Neuropsychology
Chair: W. Wölwer, Düsseldorf, Germany

O-02-001
Social motor coordination in schizophrenia patients: a new clinical perspective
D. Capdevielle, Montpellier, France

O-02-002
To trust or not to trust: the dynamics of social interactions in early psychosis
A.-K. Fett, Amsterdam, The Netherlands
S. S. Shergill, P. M. Gromann, D. W. Joyce, L. Krabbendam

O-02-003
Is the theory of mind deficit in schizophrenia explained by an impaired attention toward faces?
P. Roux, Paris, France
B. Forgeot d’Arc, C. Passerieux, F. Ramus

O-02-004
To see, or not to see: that is the question. The “Protection-Against-Schizophrenia” (PAS) model
S. Landgraf, Regensburg, Germany

O-02-005
Associations between metamemory and neurocognitive abilities in schizophrenia
S. Eifler, Mannheim, Germany

O-02-006
The relationship between stress and cognitive performance in real life environments in patients with schizophrenia
B. Wright, London, United Kingdom
E. Peters, E. Kuipers, V. Kumari
### S-15 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30 – 12.00 h</td>
<td>Humboldt Hall</td>
<td>The future of psychopathology in the light of current neuroscience</td>
<td>O. Gruber, Göttingen, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>W. Gaebel, Düsseldorf, Germany</td>
</tr>
</tbody>
</table>

**S-15-001**
RDoC and the future classification of schizophrenia spectrum disorders  
*B. N. Cuthbert, Bethesda, USA*

**S-15-002**
Modular psychopathology and symptom dimensions in schizophrenia  
*W. Gaebel, Düsseldorf, Germany*

**S-15-003**
Neuroimaging of symptoms and endophenotypic brain dysfunctions in schizophrenia: psychopatho(physio)logy of the future?  
*O. Gruber, Göttingen, Germany*

**S-15-004**
Symptom dimensions and brain systems: their roles for understanding and treatment of schizophrenia spectrum disorders  
*W. Strik, Bern, Switzerland*  
*J. Kindler, P. Homann, A. Wopfner, K. Stegmayer, H. Horn, T. Dierks*

### S-16 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30 – 12.00 h</td>
<td>Kleist Hall</td>
<td>New approaches to cognitive behavior therapy for psychosis</td>
<td>T. Kircher, Marburg, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>J. Klosterkötter, Cologne, Germany</td>
</tr>
</tbody>
</table>

**S-16-001**
Cognitive biases as moderators and mediators of successful CBTp  
*S. Mehl, Marburg, Germany*

**S-16-002**
Psychotherapy in subjects at high mental risk state  
*A. Bechdolf, Berlin, Germany*

**S-16-003**
How does CBT effect the brain of patients with schizophrenia: a multicenter fMRI study  
*A. Krug, Marburg, Germany*

**S-16-004**
Who benefits and why? Predictors of change and drop-out during cognitive behavioural therapy for psychosis  
*T. Lincoln, Hamburg, Germany*  
*S. Mehl, S. Westermann, M. Ziegler, M.-L. Kesting, E. Luellmann, W. Rief*

### PL-03 PLENARY LECTURES

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.15 – 13.00 h</td>
<td>Humboldt Hall</td>
<td>Structure and function of the human brain at the level of receptors and neural systems: a basis for psychiatric research</td>
<td>W. Maier, Bonn, Germany</td>
</tr>
</tbody>
</table>

**PL-03-001**
Structure and function of the human brain at the level of receptors and neural systems: a basis for psychiatric research  
*K. Zilles, Aachen, Germany*
FRI}, 27 SEPTEMBER 2013 – SCIENTIFIC PROGRAMME

**S-17 SYMPOSIA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30 – 12.00 h</td>
<td>Loft A</td>
<td>Epigenetic dysregulation in schizophrenia</td>
<td>P. Falkai, Munich, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A. Fischer, Göttingen, Germany</td>
</tr>
</tbody>
</table>

**S-17-001**
Cognitive symptoms in schizophrenia – pharmacological aspects of a core symptom domain  
*W. Fleischhacker, Innsbruck, Austria*

**S-17-002**
Molecular basis of epigenetic regulation  
*A. Fischer, Göttingen, Germany*

**S-17-003**
HDACi for the treatment of schizophrenia – preclinical and clinical aspects  
*A. Hasan, Munich, Germany*

**S-17-004**
Epigenetic therapies in oncology – clinical and safety aspects  
*M. Bitzer, Tübingen, Germany*

**O-03 ORAL PRESENTATIONS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30 – 12.00 h</td>
<td>Einstein Hall</td>
<td>Functional neuroimaging</td>
<td>A. Aleman, Groningen, The Netherlands</td>
</tr>
</tbody>
</table>

**O-03-001**
Phenotyping schizophrenia by multi-modal brain imaging  
*U. Schall, Callaghan, Australia*

**O-03-002**
Working memory dependent prefrontal-parietal connectivity and model-based diagnostic classification in schizophrenia  
*L. Deserno, Berlin, Germany*  
*K. H. Brodersen, Z. Lin, W. D. Penny, A. Heinz, K. E. Stephan, F. Schlagenhau*

**O-03-003**
Shared brain phenotypes for working memory dysfunction among schizophrenia and bipolar disorder  
*M. Green, Sydney, Australia*  
*Y. Quide, A. Shepherd, R. Morris, J. Rowland, P. Mitchell, V. Carr*

**O-03-004**
Alterations in the theory of mind network in unaffected first-degree relatives of patients with schizophrenia  
*H. Walter, Berlin, Germany*  
*S. Mohnke, S. Erk, N. Seiferth, O. Grimm, L. Haddad, K. Schnell, M. Nöthen, A. Heinz, A. Meyer-Lindenberg*

**O-03-005**
Reduced activation in nucleus accumbens and ventral tegmental area during probabilistic decision-making in schizophrenia  
*F. Rausch, Mannheim, Germany*  

**O-03-006**
Abnormal delta oscillatory activity during acute psychotic episode in schizophrenia: a MEG study  
*J. Tarrago, Barcelona, Spain*  
*R. Novak, C. Alonso, O. Pino, E. Rojo*
P-05 POSTER SESSIONS

13.30 – 14.30 h Foyer
Neurobiology and genetics
Chair: T. Schulze, Göttingen, Germany

P-05-001
Glutamate concentrations and performance during operant conditioning in schizophrenia
T. Gleich, Berlin, Germany
R. Böhme, L. Deserno, A. Pankow, J. Gallinat, A. Heinz, F. Schlagenhauf

P-05-002
Altered adhesion and microfilament organization in neuronal precursors of schizophrenia patients: reversion by melatonin
G. Benítez-King, México-City, Mexico

P-05-003
Neuropathological finding of frontal cortex of animal model and postmortem human brain of schizophrenia
S. Iritani, Nagoya, Japan
H. Sekiguchi, C. Habuchi, K. Umeda, Y. Torii, M. Miyata, K. Fujita, N. Ozaki

P-05-004
Molecular mechanisms of visual adaptation: a role for the DTNBP1 (Dysbindin) schizophrenia risk gene in visual short-term plasticity
G. Andrade, Bronx, New York, USA
J. Butler, B. Abrahams, J. Foxe

P-05-005
Expression of DISC1 in the development of the white matter of rats
C. Li, Chongqing, People's Republic of China
L. Xiao, S. Liu, M. Wei

P-05-006
Role of CB1 receptor and endocannabinoids on cortico-striatal connectivity of psychosocially stressed mice
U. Havemann-Reinecke, Göttingen, Germany

P-05-008
Concordance and heritability in schizophrenia, register-based data from a Danish twin study
R. Hilker, Glostrup, Denmark
M. Nordentoft, D. Helenius, B. Glenthøj

P-05-009
Acute intermittent porphyria and cycloid psychosis
I. Daey Ouwens, Venray, The Netherlands

P-05-010
Kallmann syndrome and schizophrenia: is there a relationship?
W. Verhoeven, Venray, The Netherlands
J. Egger, J. Havens, N. De Leeuw, L. Hoefsloot

P-05-011
Routine screening for copy number variations in schizophrenia-spectrum disorders: relevant to clinical practice?
W. Verhoeven, Venray, The Netherlands
N. van de Kerkhof, I. Feenstra, F. van der Heijden, N. de Leeuw, J. Egger, G. Stöber
<table>
<thead>
<tr>
<th>P-06</th>
<th>POSTER SESSIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>13.30 – 14.30 h</strong></td>
<td>Foyer</td>
</tr>
<tr>
<td><strong>Functional neuroimaging</strong></td>
<td><strong>Chair:</strong> A. Heinz, Berlin, Germany</td>
</tr>
</tbody>
</table>

**P-06-001**  
Altered reinforcement learning and working memory in psychosis  
F. Schlagenhauf, Berlin, Germany

**P-06-002**  
Reinforcement learning in an uncertain environment: behavioral and neural correlates in schizophrenia patients and healthy participants with delusional experiences  
R. Boehme, Berlin, Germany  

**P-06-003**  
Model-free and model-based control in reinforcement learning: relation to dopamine synthesis and implications for schizophrenia  
L. Deserno, Berlin, Germany  
R. Böhme, A. Wilitzki, R. Buchert, Q. Huys, S. Florian

**P-06-004**  
Neural correlates of action and expected value during the anticipation of monetary reward  
Y. Fukuda, Berlin, Germany  
L. Deserno, S. Koch, F. Schlagenhauf

**P-06-005**  
Aberrant brain reward response in siblings of patients with psychosis during trust-related behaviour  
P. Gromann, Amsterdam, The Netherlands  
S. Shergill, L. de Haan, D. Meewis, A.-K. Fett, L. Krabbendam

**P-06-006**  
Improvement of brain reward abnormalities related to Dopamine D2/D3 receptor blockade – a study in antipsychotic-naive first-episode schizophrenia patients  
S. Wulff, Glostrup, Denmark  
M. Ø. Nielsen, E. Rostrup, B. Y. Glenthøj

**P-06-007**  
Altered default mode network activity in schizophrenia patients  
A. Pankow, Berlin, Germany  

**P-06-008**  
Self-reference processing in schizophrenia and psychotic experiences – an fMRI study  
T. Katthagen, Berlin, Germany  
A. Pankow, L. Deseno, M. Gaebler, A. Heinz, F. Schlagenhauf

**P-06-009**  
Brief monocular deprivation as an assay of short-term visual sensory plasticity in schizophrenia – “the binocular effect”  
J. Foxe, Bronx, USA  
S. Yeap, V. Leavitt

**P-06-010**  
Obsessive-compulsive symptoms in schizophrenia are associated with more activation of the orbito-frontal cortex  
F. Schirmbeck, Mannheim, Germany  
D. Mier, C. Esslinger, F. Rausch, S. Eifler, S. Englisch, A. Meyer-Lindenberg, P. Kirsch, M. Zink
**P-07**

**POSTER SESSIONS**

13.30 – 14.30 h  
Foyer

**Research methods and health service research**

*Chair:* to be announced

---

**P-07-002**

The early recognition inventory ERlaos detects at risk mental states of psychosis with high sensitivity  
*F. Rausch, Mannheim, Germany*  
*S. Eifler, A. Esser, C. Esslinger, F. Schirmbeck, A. Meyer-Lindenberg, M. Zink*

---

**P-07-003**

Assessment of prodromal symptoms in incipient psychotic disorders: reliability and validity measures of the Early Recognition Inventory-Spanish Version (ERlaos-SV)  
*S. Ochoa, Sant Boi de Llobregat, Spain*  
*A. Barajas, A. Farreny, R. Rodriguez-Jimenez, M. Moreno, R. Landín-Romero, C. Bayon, A. Ibanez, B. Cabrera, M. A. Quintanilla, J. Usall*

---

**P-07-004**

“*It was easier than dealing with a pen and paper...”*: exploring the usability of electronic devices for completion of Clinical Outcome Assessments (COAs) in schizophrenia  
*C. Tolley, Bollington, UK*  
*D. Rofail, A. Gater*

---

**P-07-005**

When does “Yes” mean “Yes”: is parental consent a necessary component of obtaining informed consent from minors in Canada’s indigenous context  
*C. Cheng, Thunder Bay, Canada*  
*J. Fogolin, M. Katt, S. Nadin, P. Braunberger, J. B. Minore, C. S. Dewa*

---

**P-07-007**

Changing attitude towards schizophrenia by psychiatric training of medical students  
*F. Lang, Guenzburg, Germany*  
*M. Kösters, S. Lang, T. Becker, M. Jäger*

---

**P-07-008**

Assessment on the impact of financial crisis on the access to mental health services in Greece  
*E. Neroutsos, Elefsina-Athens, Greece*  
*A. Pachi, M. Fiste, E. Kontomina, E. Bisbiki, N. Lytra*

---

**P-07-009**

First Spanish virtual community for people who hear voices  
*M. J. Escarti Fabra, Valencia, Spain*  
*E. Lorente Rovira, A. Luengo Martin, E. Aguilar, J. Sanjuán Arias*

---

**P-07-010**

State and problems of psychiatric care in Kazakhstan (focus on schizophrenia)  
*S. Nurmagambetova, Almaty, Kazakhstan*  
*M. Assimov*
### P-08 POSTER SESSIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.30 – 14.30 h</td>
<td>Foyer</td>
<td>Neuropsychology 2</td>
<td>Chair: P. Ward, Liverpool, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>P-08-001</strong></td>
<td>Cognitive impairments are linearly related to psychometric risk for schizophrenia-spectrum disorders</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Giakoumaki, Rethymno, Greece</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Roussos, C. Zouraraki, P. Bitsios</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>P-08-002</strong></td>
<td>Is the tendency to extract meaning from auditory noise associated with schizotypy?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Morton, Dunedin, New Zealand</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Nicolson, R. J. Linscott</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>P-08-003</strong></td>
<td>Schizotypal traits in a community sample: characteristics and neuropsychological correlates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Tesse, London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>P-08-004</strong></td>
<td>Schizotypal traits in a non-clinical population based sample: characteristics and neuropsychological performance profiles</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Tesse, London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>P-08-005</strong></td>
<td>Neurocognitive performance in treatment-resistant and non-treatment-resistant schizophrenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>V. Anderson, Auckland, New Zealand</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. McIlwain, C. McNabb, R. Kydd, B. Russell</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>P-08-006</strong></td>
<td>Cognitive functioning in individuals aged &gt;65 years with ‘very-late-onset schizophrenia-like-psychosis’ (VLOSLP), chronic schizophrenia and late-onset psychotic depression</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Simpson, The Ponds, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>R. Langdon, J. Batchelor, A. Falcon, S. Tyagi</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>P-08-007</strong></td>
<td>A comprehensive neuropsychological study of individuals with very-late-onset schizophrenia-like-psychosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Simpson, The Ponds, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>R. Langdon, J. Batchelor, A. Falcon, S. Tyagi</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>P-08-008</strong></td>
<td>The relationship between noise-induced stress and cognitive performance in patients with schizophrenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Wright, London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. Peters, E. Kuipers, V. Kumari</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>P-08-009</strong></td>
<td>The MATRICS Consensus Cognitive Battery (MCCB) in Norway: associations with IQ, clinical and occupational measures</td>
</tr>
<tr>
<td></td>
<td></td>
<td>J. Lystad, Oslo, Norway</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. Falkum, H. Bull, C. Mohn, B. Rishovd Rund, T. Ueland</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>P-08-010</strong></td>
<td>The relation between insight and use of feedback on the Wisconsin Card Sorting Test in patients with schizophrenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. de Vos, Assen, The Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. Pijnenborg, A. Aleman, L. van der Meer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>P-08-011</strong></td>
<td>Influence of gender on the primacy and recency effect in patients with a first-episode psychosis and schizophrenia patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. Huerta-Ramos, Sant Boi de Llobregat, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Butjosa Malines, C. Núñez Leánez, J. Usalli Rodiè, A. Barajas Vélez, A. Foix Sanjuan, M. Dolz Abadia, S. Ochoa Güerre</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>P-08-013</strong></td>
<td>Relation between jumping to conclusions (JTC) and neuropsychological performance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Ochoa, Sant Boi de Llobregat, Spain</td>
<td></td>
</tr>
</tbody>
</table>
### P-09-001
Sexual adverse effects and antipsychotic-induced hyperprolactinemia: a cross-sectional study  
J. Usall, Sant Boi de Llobregat, Spain  
R. Cambra, E. Rubio-Abadal, G. Saenz Navarrete, B. Arranz, N. del Cacho, R. Iniesta, M. Roca, V. Barneda

### P-09-002
Sexual dysfunction in schizophrenic and schizoaffective patients treated with antipsychotics  
M. Del Carmen García Mahia, A Coruña, Spain  
M. Vidal Millares, E. Roman Fernandez

### P-09-003
Psychiatric and non-psychiatric comorbidity in schizophrenic patients treated with antipsychotics  
M. Del Carmen García Mahia, A Coruña, Spain  
M. Vidal Millares, J. A. Amado García

### P-09-004
Comparative assessment of the social performances for schizophrenic patients treated with long acting antipsychotics  
M. C. Pirlog, Craiova, Romania  
I. Marinescu, D. Marinescu

### P-09-005
Antipsychotics and antidepressants and their associations with suicidal ideation – the Northern Finland Birth Cohort 1966 study  
I. Rissanen, Oulu, Finland  
E. Jääskeläinen, M. Isohanni, H. Koponen, M. Joukamaa, A. Alaräisänen, J. Miettunen

### P-09-006
Involuntary hospitalization and the course of medication adherence, treatment engagement and perception of coercion  
S. Jaeger, Ravensburg, Germany  

### P-09-007
Long-term effects of prefrontal rTMS on cognitive functioning in schizophrenia  
C. Kos, Groningen, The Netherlands  
J. Dlabac-de Lange, L. Bais, R. Knegtering, A. Aleman

### P-09-008
Trends in the administration of electroconvulsive therapy for schizophrenia in Colombia. Descriptive study and literature review  
G. Oviedo, Bogotá, Colombia  

### P-09-009
Sleep prolongation may decrease level of self-reported sleepiness but not slow wave activity in electroencephalogram (EEG) in patients with schizophrenia  
M. Jarema, Warsaw, Poland  
L. Okruszek, A. Wchniajk, A. Wierzbicka, E. Walinowska, K. Czesak, I. Musinska, T. Jakubczyk, W. Jernajczyk M.D.

### P-09-010
Can work history at baseline predict work behavior within the first four weeks of vocational rehabilitation?  
H. Bull, Oslo, Norway  
T. Ueland, J. Ullevoldsæter Lystad, E. Falkum
From Therapy to Prevention

SELECTION OF LECTURES

<table>
<thead>
<tr>
<th>Lecture</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>What can Psychiatry contribute to the understanding of extreme violence?</td>
<td>Ulrik Malt (Oslo, Norway)</td>
</tr>
<tr>
<td>Mental Health of European youth and scientific evidence for the suicide treatment and prevention</td>
<td>Danuta Wasserman (Stockholm, Sweden)</td>
</tr>
<tr>
<td>Future of psychiatric services in the 21st century</td>
<td>Dinesh Bhugra (London, United Kingdom)</td>
</tr>
<tr>
<td>Mental disorders and their care through history in Egypt</td>
<td>Tarek A. Okasha (Kairo, Egypt)</td>
</tr>
<tr>
<td>Psychiatric Diagnosis: its past, present, and future</td>
<td>Allen J. Frances (Coronado, USA)</td>
</tr>
</tbody>
</table>

CME certified

English programme track

Congress Organiser
German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)
Reinhardtstraße 37 B, 10117 Berlin, Germany
TEL: +49 (0) 30–240 477 20
programm@dgppn.de

Congress and Exhibition Office
CPO HANSER SERVICE GmbH, Office Berlin
Paulsborner Straße 44, 14193 Berlin, Germany
TEL: +49 (0) 30–300 669 0
dgppn13@cpo-hanser.de
<table>
<thead>
<tr>
<th><strong>S-22</strong></th>
<th><strong>SYMPOSIA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.30 – 16.00 h</strong></td>
<td>Humboldt Hall</td>
</tr>
<tr>
<td><strong>From structure to functioning:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>neurobiological candidates for</strong></td>
<td></td>
</tr>
<tr>
<td><strong>the prediction of psychoses</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chairs:</strong></td>
<td></td>
</tr>
<tr>
<td>S. Ruhrmann, Cologne, Germany</td>
<td></td>
</tr>
<tr>
<td>S. Wood, Birmingham, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

**S-22-001**
The contribution of structural brain imaging to the prediction of psychoses
N. Koutsouleris, Munich, Germany

**S-22-002**
The contribution of MR spectroscopy to the prediction of psychoses
S. Wood, Birmingham, United Kingdom

**S-22-003**
The contribution of functional imaging to the prediction of psychoses
S. Borgwardt, Basel, Switzerland

**S-22-004**
Contributions of cognitive neurophysiology to prediction of psychotic disorders
S. Ruhrmann, Cologne, Germany
S. Mueller, M. Bodatsch, J. Klosterkoetter

<table>
<thead>
<tr>
<th><strong>S-19</strong></th>
<th><strong>SYMPOSIA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.30 – 16.00 h</strong></td>
<td>Kleist Hall</td>
</tr>
<tr>
<td><strong>Should continuous antipsychotic medication be recommended after first episode psychosis?</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Chairs:</strong></td>
<td></td>
</tr>
<tr>
<td>M. Nordentoft, Copenhagen, Denmark</td>
<td></td>
</tr>
<tr>
<td>L. Wunderink, Groningen, The Netherlands</td>
<td></td>
</tr>
</tbody>
</table>

**S-19-001**
Remission of psychotic symptoms and antipsychotic medication – long term follow-up of first episode patients included in the TIPS project
I. Melle, Haslum, Norway

**S-19-002**
A focus on poor physical health in psychosis: from animal data to the long-term follow-up of first episode patients from the AESOP study
V. Mondelli, London, United Kingdom
P. Dazzan

**S-19-003**
Remission of antipsychotic medication and remission of psychotic symptoms – long term follow-up of first episode patients included in the OPUS trial
M. Nordentoft, Copenhagen, Denmark
S. Austin, O. Mors

**S-19-004**
Recovery in remitted first episode psychosis at 7-years of follow-up of an early dose-reduction/discontinuation or maintenance treatment strategy
L. Wunderink, Groningen, The Netherlands
D. Wiersma, S. Sytema, F. Nienhuis
**Friday, 27 September 2013 – SCIENTIFIC PROGRAMME**

<table>
<thead>
<tr>
<th><strong>S-20</strong> SYMPOSIA</th>
<th>14.30 – 16.00 h</th>
<th>Loft A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The role of neuroinflammation in schizophrenia</strong>&lt;br&gt;Chairs: A. J. Tanra, Makassar, Indonesia&lt;br&gt;M. Ohgidani, Fukuoka, Japan</td>
<td><strong>S-20-001</strong></td>
<td>Antipsychotics and minocycline as a possible modulator of microglial inflammatory/oxidative stress response in schizophrenia&lt;br&gt;M. Ohgidani, Fukuoka, Japan&lt;br&gt;T. Kato</td>
</tr>
<tr>
<td><strong>S-20-002</strong></td>
<td>Immature dentate gyrus and mild chronic inflammation: candidate endophenotype of neuropsychiatric disorders&lt;br&gt;T. Miyakawa, Toyoake, Japan</td>
<td></td>
</tr>
<tr>
<td><strong>S-20-003</strong></td>
<td>Low dose of Dextromethorphan may benefit in schizophrenia treatment&lt;br&gt;R.-B. Lu, Tainan City, Taiwan</td>
<td></td>
</tr>
<tr>
<td><strong>S-20-004</strong></td>
<td>The effects of minocycline on microglial cells activation in the dentate gyrus of Gunn rat: a possible animal model of schizophrenia&lt;br&gt;A. J. Tanra, Makassar, Indonesia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>S-21</strong> SYMPOSIA</th>
<th>14.30 – 16.00 h</th>
<th>Einstein Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Experimental psychopathology of psychosis</strong>&lt;br&gt;Chairs: M. Voss, Berlin, Germany&lt;br&gt;P. Uhlhaas, Glasgow, United Kingdom</td>
<td><strong>S-21-001</strong></td>
<td>Delusions and the role of beliefs in perceptual inference&lt;br&gt;P. Sterzer, Berlin, Germany</td>
</tr>
<tr>
<td><strong>S-21-002</strong></td>
<td>Psychophysical and neurochemical aspects of context perception in schizophrenia&lt;br&gt;J. Terock, Luebeck, Germany&lt;br&gt;B. Zurowski</td>
<td></td>
</tr>
<tr>
<td><strong>S-21-003</strong></td>
<td>Disturbances in the sense of agency in schizophrenia&lt;br&gt;M. Voss, Berlin, Germany</td>
<td></td>
</tr>
<tr>
<td><strong>S-21-004</strong></td>
<td>High-frequency oscillations in schizophrenia: a translational perspective&lt;br&gt;P. Uhlhaas, Glasgow, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>W-02</strong> WORKSHOPS</th>
<th>14.30 – 16.00 h</th>
<th>Loft C</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>How to apply for EU funding</strong>&lt;br&gt;Chair: S. Rauschen, Bonn, Germany</td>
<td><strong>S-21-001</strong></td>
<td>Antipsychotics and minocycline as a possible modulator of microglial inflammatory/oxidative stress response in schizophrenia&lt;br&gt;M. Ohgidani, Fukuoka, Japan&lt;br&gt;T. Kato</td>
</tr>
<tr>
<td><strong>S-20-002</strong></td>
<td>Immature dentate gyrus and mild chronic inflammation: candidate endophenotype of neuropsychiatric disorders&lt;br&gt;T. Miyakawa, Toyoake, Japan</td>
<td></td>
</tr>
<tr>
<td><strong>S-20-003</strong></td>
<td>Low dose of Dextromethorphan may benefit in schizophrenia treatment&lt;br&gt;R.-B. Lu, Tainan City, Taiwan</td>
<td></td>
</tr>
<tr>
<td><strong>S-20-004</strong></td>
<td>The effects of minocycline on microglial cells activation in the dentate gyrus of Gunn rat: a possible animal model of schizophrenia&lt;br&gt;A. J. Tanra, Makassar, Indonesia</td>
<td></td>
</tr>
</tbody>
</table>
### S-18 SYMPOSIA

**16.30 – 18.00 h**

**Humboldt Hall**

**Perspectives in schizophrenia research: emerging research issues**

Organised by the European Scientific Association on Schizophrenia and other Psychoses (ESAS)

*Chairs: W. Gaebel, Düsseldorf, Germany*  
*S. Galderisi, Naples, Italy*

| S-18-001 | Emerging research issues in biological and translational research  
| P. Falkai, Munich, Germany / W. Maier, Bonn, Germany |
| S-18-002 | Emerging research issues concerning drug and other somatic treatments  
| H.-J. Möller, Munich, Germany |
| S-18-003 | Emerging research issues concerning psycho-social interventions  
| W. Rössler, Zurich, Switzerland |
| S-18-004 | Emerging research issues toward recovery: the case of negative and cognitive symptoms  
| S. Galderisi, Naples, Italy |

### S-23 SYMPOSIA

**16.30 – 18.00 h**

**Kleist Hall**

**Implementation of early intervention services for young people with first episode psychosis: rationale, evidence and practical experiences from Europe**

*Chairs: A. Bechdolf, Berlin, Germany*  
*M. Birchwood, Birmingham, United Kingdom*

| S-23-001 | Why do we need specialized early intervention in first episode psychosis?  
| A. Bechdolf, Berlin, Germany |
| S-23-002 | The early intervention service reform in the UK: outcomes and the next wave of reform  
| M. Birchwood, Birmingham, United Kingdom |
| S-23-003 | The EPPIC follow-up study: baseline clinical characteristics and longer-term outcome of first-episode schizophrenia  
| G. P. Amminger, Parkville, Australia |
| S-23-004 | Implementation of early intervention services in Denmark – from research to practice  
| M. Nordentoft, Copenhagen, Denmark |
**S-24** SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Details</th>
</tr>
</thead>
</table>
| 16.30 – 18.00 h | Loft A | Studies using structural and functional neuroimaging to advance understanding of schizophrenia  
*Chairs: S. Hodgins, Montreal, Canada  
B. Schiffer, Bochum, Germany*  

**S-24-001**  
Altered contextual modulation of primary visual cortex responses in schizophrenia  
P. Sterzer, Berlin, Germany  
K. Seymour  

**S-24-002**  
Mentalizing abilities and their neural underpinnings in different types of offenders with schizophrenia  
B. Schiffer, Bochum, Germany  

**S-24-003**  
Animacy experience and mentalizing in schizophrenia spectrum disorders who engage in violent offending  
C. Pawliczek, Aachen, Germany  
B. Schiffer  

**S-24-004**  
Grey matter density in different types of violent offenders with schizophrenia  
S. Hodgins, Montreal, Canada  
B. Schiffer

**O-04** ORAL PRESENTATIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Details</th>
</tr>
</thead>
</table>
| 16.30 – 18.00 h | Einstein Hall | Comorbidity  
*Chair: N. Sartorius, Geneva, Switzerland*  

**O-04-001**  
The role of striatal dopamine in co-morbid addictive states in schizophrenia – revisiting the „self-medication hypothesis”  
A. G. Awad, Toronto, Canada  

**O-04-002**  
The role of substance abuse in prediction of long-term outcome of schizophrenia – systematic review and meta-analysis  
J. Miettunen, Oulu, Finland  
K. Kasurinen, N. Hirvonen, E. Oinas, J. Käkelä, E. Jääskeläinen, A. Alaräsänen  

**O-04-003**  
Is there a relation between reward-disturbances and weight gain caused by antipsychotic medication in patients with schizophrenia?  
M. Nielsen, Roskilde, Denmark  
S. Wulff, B. Broberg, E. Rostrup, B. Glenthøj  

**O-04-004**  
Association between cognitive deficits and obsessive-compulsive symptoms in patients with psychosis and unaffected siblings: a 3 year follow-up  
F. Schirmbeck, Mannheim, Germany  
M. Swets, M. Zink, R. Kahn, J. van Os, R. Bruggeman, W. Cahn, A. Bartels, C. J. Meijer, I. Myin-Germeys, L. de Haan  

**O-04-005**  
Dissociation and social cognition in schizophrenia spectrum disorder  
S. Renard, Groningen, The Netherlands  
M. Pijnenborg, P. Lysaker  

**O-04-006**  
Multimorbidity in psychotic disorders and their unaffected siblings: an epidemiological perspective  
M. A. Islam, Groningen, The Netherlands  
M. F. Khan, P. J. Quee, H. Snieder, E. R. van den Heuvel, R. Bruggeman, B. Z. Alizadeh
S-25 SYMPOSIAS
18.15 – 19.45 h Humboldt Hall
Nosology in the schizophrenic psychoses: new insight from functional neuroimaging and genetics
Chairs: B. Pfuhlmann, Wuerzburg, Germany
        J. Foucher, Strasbourg, France

S-25-001
Cycloid psychosis in a Dutch psychiatric teaching hospital: relevance for diagnosis, treatment and prognosis
W. Verhoeven, Venray, The Netherlands
N. van de Kerkhof, F. Van der Heijden, M. Schneider, G. Stöber

S-25-002
Genome-wide search for de novo copy-number variations (CNVs) in cycloid psychoses and chronic schizophrenic psychoses with phenotype correlation
M. Gawlik, Cardiff, United Kingdom
G. Kirov, E. Rees, L. Georgieva, G. Stoeber

S-25-003
Functional integration in cycloid psychosis and affect-laden paraphrenia: a double dissociation within the DSM-IV diagnosis of schizophrenia
J. Foucher, Strasbourg, France

S-25-004
New genetic loci for periodic catatonia on chromosome 7p14.1 and 19p12 in a genome-wide association study with pooled DNA
G. Stöber, Wuerzburg, Germany
D. Schanze, A. B. Ekici, B. Pfuhlmann, A. Reis

S-26 SYMPOSIAS
18.15 – 19.45 h Kleist Hall
The consequences of childhood trauma in psychotic disorders
Chairs: I. Melle, Haslum, Norway
        M. Aas, Oslo, Norway

S-26-001
Childhood trauma and clinical features in bipolar disorder
I. Melle, Haslum, Norway
B. Etain, M. Aas, O. A. Andreassen, F. Bellivier, C. Henry

S-26-002
Biological pathways between childhood trauma and psychosis onset
V. Mondelli, London, United Kingdom

S-26-003
Trauma and neglect in first episode psychosis: preliminary results 2
A. M. Trauelsen, Copenhagen, Denmark

S-26-004
Interactions between BDNF Val66Met, childhood adverse events and brain volume abnormalities in schizophrenia and bipolar disorders
M. Aas, Oslo, Norway
U. K. Haukvik, S. Djurovic, Ø. Bergmann, S. Lorentzen, O. A. Andreassen, I. Agartz, I. Melle
### S-27 SYMPOSIA

<table>
<thead>
<tr>
<th>18.15 – 19.45 h</th>
<th>Loft A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Progress in neuropathological post-mortem findings in schizophrenia</strong></td>
<td></td>
</tr>
</tbody>
</table>
| *Chairs:* A. Schmitt, Munich, Germany  
J. Steiner, Magdeburg, Germany |

#### S-27-001

**Neuropathological assessment of autopsy cases with schizophrenia – recommendations of the Brain Net Europe Consortium**  
T. Arzberger, Munich, Germany

#### S-27-002

**Histological and gene expression studies of the hippocampus in schizophrenia**  
A. Schmitt, Munich, Germany  
H.-G. Bernstein, J. Steiner, C. Schmitz, B. Bogerts, M. Rossner, P. Falkai

#### S-27-003

**Oligodendrocytes in schizophrenia**  
J. Steiner, Magdeburg, Germany  
H.-G. Bernstein, B. Bogerts

#### S-27-004

**Applying proteomics to schizophrenia post-mortem brain tissue**  
D. Martins-de-Souza, Munich, Germany

---

### O-05 ORAL PRESENTATIONS

<table>
<thead>
<tr>
<th>18.15 – 19.45 h</th>
<th>Einstein Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Course and outcome</strong></td>
<td></td>
</tr>
<tr>
<td><em>Chair:</em> V. W. Larach, Santiago, Chile</td>
<td></td>
</tr>
</tbody>
</table>

#### O-05-001

**Gender differences in first episode psychosis at five-year follow-up – two different courses of disease?**  
A. Thorup, Copenhagen, Denmark  
N. Albert, B. Mette, L. Petersen, P. Jeppesen, P. Le Quarck, M. Nordentoft

#### O-05-002

**Association of familial risk to social, occupational and global outcome in schizophrenia – systematic review and meta-analysis**  
J. Käkelä, Oulu, Finland  
E. Oinas, E. Jääskeläinen, J. Miettunen

#### O-05-003

**The characteristics of self-experiences and the quality of life in persons with schizophrenia and those after spinal-cord injury**  
B. Horvat, Velika Polana, Slovenia

#### O-05-004

**Quality of life and internalized stigma in patients with schizophrenia: examining the influence of clinical diagnostic and treatment setting**  
S. Oliveira, Lisboa, Portugal  
F. Esteves

#### O-05-006 (former O-06-007)

**Helping people with psychotic disorders back to work – the JUMP study**  
E. Falkum, Oslo, Norway  
J. Lystad, H. Bull, S. Evensen, T. Ueland
**S-28 SYMPOSIA**

08.30 – 10.00 h Humboldt Hall

The high risk state for psychosis

*Chairs: J. Klosterkötter, Cologne, Germany P. Fusar-Poli, London, United Kingdom*

**S-28-001**

The ultra high risk approach – current state and future directions

P. Fusar-Poli, London, United Kingdom

A. Yung

**S-28-002**

The basic symptom approach for identifying individuals at high risk

J. Klosterkötter, Cologne, Germany

**S-28-003**

The impact of social functioning and Axis-1 diagnoses

R. K. R. Salokangas, Turku, Finland

S. Ruhrmann, H. Graf von Reventlow, M. Heinimaa, S. Luutonen, T. From, G. Juckel, D. Linszen, P. Dingemans, M. Birchwood, P. Patterson, J. Klosterkötter

**S-28-004**

Searching for neuroimaging markers of the high-risk state of psychosis

S. Borgwardt, Basel, Switzerland

---

**S-29 SYMPOSIA**

08.30 – 10.00 h Kleist Hall

The role of oligodendrocytes in schizophrenia: disease-inherent versus treatment-induced abnormalities

*Chairs: J. Steiner, Magdeburg, Germany N. Uranova, Moscow, Russia*

**S-29-001**

Ultrastructural alterations of myelinated fibers and oligodendrocytes in schizophrenia

N. Uranova, Moscow, Russia

V. Shklover, O. Vikhreva, V. Rachmanova, D. Orlovskaya, P. Kazanskiy, V. Chelpanov

**S-29-002**

Oligodendrocyte dysfunction in schizophrenia by proteomics

D. Martins-de-Souza, Munich, Germany

**S-29-003**

Animal experiment data regarding the effect of antipsychotic drugs on oligodendrocyte turnover

L. Xiao, Chongqing, People's Republic of China

H. Wang, J. Niu, H. Wang

**S-29-004**

Protective role of haloperidol and clozapine on energy-deprived oligodendrocytes in culture

J. Steiner, Magdeburg, Germany

H.-G. Bernstein, B. Bogerts, G. Keilhoff
S-30 SYMPOSIA

08.30 – 10.00 h  Loft A

Oscillations and synchrony in cortical networks in schizophrenia
Jointly organised by the Asian Network for Schizophrenia Research (ANSR) and the European Scientific Association on Schizophrenia and other Psychoses (ESAS)
Chairs: J. S. Kwon, Seoul, Republic of Korea
S. Ruhrmann, Cologne, Germany

S-30-001
Oscillations and synchrony in animal models of schizophrenia
T. Sigurdsson, Frankfurt am Main, Germany

S-30-002
High-frequency oscillations in schizophrenia: perspectives from MEG
P. Uhlhaas, Glasgow, United Kingdom

S-30-003
Altered oscillatory activity in the alpha-theta frequency range in schizophrenia patients
R. Müller, Cologne, Germany
S. Ruhrmann

S-30-004
Abnormal oscillations and synchrony of MEG in ultra-high risk subjects for psychosis
J. S. Kwon, Seoul, Republic of Korea

O-06 ORAL PRESENTATIONS

08.30 – 10.00 h  Einstein Hall

Treatment
Chair: A. G. Awad, Toronto, Canada

O-06-001
Waiting for godot
D. Goel, Invercargill, New Zealand

O-06-002
Preliminary results of the Neuroleptic Strategy Study (NeSSy)
M. Heinze, Ruedersdorf, Germany

O-06-003
Working out first-episode schizophrenia: neuropsychological, cognitive and clinical changes following an aerobic exercise intervention
P. Ward, Liverpool, Australia

O-06-005
Does one program look like the other? A systematic review of practices to measure fidelity to early psychosis intervention standards
C. Cheng, Thunder Bay, Canada
A. Selick, J. Durbin, S. Moss

O-06-006
Effectiveness of a community-based early intervention program for psychosis: baseline characteristics and three-month follow-up
J. Barglow, New York, USA
T. Dole, M. Birnbaum

O-06-007 (former O-05-006)
Relapses during long-term hospitalization of people suffering from schizophrenia
G. Bogojevic, Belgrade, Serbia
D. Zigmund, L. Ziravac, U. Pavic
**S-31 SYMPOSIA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30 – 12.00 h</td>
<td>Humboldt Hall</td>
<td>Indicated prevention of psychosis</td>
<td>J. Klosterkötter, Cologne, Germany M. Birchwood, Birmingham, United Kingdom</td>
</tr>
</tbody>
</table>

**S-31-001**
Interventions in people at high risk of psychosis: results of randomized controlled trials
A. Bechdolf, Berlin, Germany

**S-31-002**
Omega-3 fatty acids for indicated prevention: treatment results and pathomechanisms
G. P. Amminger, Parkville, Australia
M. S. Harris, P. D. McGorry, L. P. Henry

**S-31-003**
MindNet: a new model of implementation of early intervention services
M. Lambert, Hamburg, Germany

**S-31-004**
From risk factors to resilience: perspectives for the prevention of mental disorders
S. Ruhrmann, Cologne, Germany

**PL-04 PLENARY LECTURES**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.15 – 13.00 h</td>
<td>Humboldt Hall</td>
<td>Twenty years of early intervention in psychosis: how critical is the critical period hypothesis?</td>
<td>J. Klosterkötter, Cologne, Germany</td>
</tr>
</tbody>
</table>

**W-03 WORKSHOPS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30 – 12.00 h</td>
<td>Kleist Hall</td>
<td>International perspectives of quality of care and integration of persons with schizophrenia</td>
<td>A. Javed, Nuneaton, United Kingdom W. Gaebel, Düsseldorf, Germany</td>
</tr>
</tbody>
</table>

**W-03-001**
Long term outcome of schizophrenia in developing and developed countries
N. Sartorius, Geneva, Switzerland

**W-03-002**
Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle income countries
A. Lora, Lecco, Italy

**W-03-003**
The developing countries view on ensuring quality of care
A. Javed, Nuneaton, United Kingdom

**W-03-004**
Strategy for management of first psychotic episode supported by state law guarantees in a middle-income country
V. W. Larach, Santiago, Chile

**W-03-005**
Towards a global definition of quality of mental health services—lessons learned from developing a respective EPA guidance
W. Gaebel, Düsseldorf, Germany
### S-32 SYMPOSIA

**10.30 – 12.00 h**  
Loft A

**Single symptom approaches in schizophrenia: neuronal correlates of auditory hallucinations and language related symptoms**  
*Chairs: J. Gallinat, Berlin, Germany  
T. Dierks, Bern, Switzerland*

| S-32-001 | Auditory hallucinations and the language system  
T. Dierks, Bern, Switzerland |
|---|---|
| S-32-002 | Hearing voices as a phenomenon of dysconnectivity?  
C. Mulert, Hamburg, Germany |
| S-32-003 | Auditory hallucinations and ego-disturbances: imaging of dysfunctional brain networks  
J. Gallinat, Berlin, Germany |
| S-32-004 | Non-invasive brain stimulation for the treatment of schizophrenia: neurobiological and clinical aspects  
A. Hasan, Munich, Germany |

### S-33 SYMPOSIA

**10.30 – 12.00 h**  
Einstein Hall

**The schizophrenia motor dimension: clinical relevance and neurobiology**  
*Chairs: S. Walther, Bern, Switzerland  
M. Morrens, Antwerp, Belgium*

| S-33-001 | Parsing the components of psychomotor functioning in schizophrenia  
M. Morrens, Antwerp, Belgium |
|---|---|
| S-33-002 | Motor signs in individuals at risk of schizophrenia  
P. N. van Harten, Maastricht, The Netherlands |
| S-33-003 | Clinical and cerebral correlates of neurological soft signs in schizophrenia  
J. Schröder, Heidelberg, Germany |
| S-33-004 | Dysfunctional subcortico-cortical interactions in the motor loop as probable cause for hypokinesia in schizophrenia  
S. Walther, Bern, Switzerland |
P-10 POSTER SESSIONS
13.30 – 14.30 h Foyer
Treatment (psychosocial) 3
Chair: T. Lincoln, Hamburg, Germany

P-10-001
Metacognitive training for patients with schizophrenia: preliminary evidence for a targeted single-module program
R. Balzan, Adelaide, Australia
P. Delfabbro, C. Galletly, T. Woodward

P-10-002
Cognitive remediation therapy in schizophrenia
M. Fiste, Chaidari-Athens, Greece
M. Papagathaggelou, N. Lytra, E. Thermou, E. Neroutsos

P-10-003
Does the integrated psychological therapy improve neurocognition and social-functioning in patients with schizophrenia?
A. Taksal, Bangalore, India
P. Sudhir, K. Kumar, J. Thirthalli, D. Vishwanath

P-10-004
Rehabilitation of communicative abilities in schizophrenic patients through the cognitive pragmatics treatment: a pilot study
F. M. Bosco, Turin, Italy

P-10-005
Cognitive-behavioral therapy and negative symptoms of schizophrenia
M. Fiste, Chaidari-Athens, Greece
E. Neroutsos, N. Lytra, G. Triantafyllou, E. Thermou

P-10-006
Effectiveness of group therapy aimed at overcoming schizophrenia
A. M. Rojas Rivera, San Antonio, Chile

P-10-007
Behavioral Activation for Negative Symptoms (BANS-NL): a nurse intervention for psychotic disorders
A. Malda, Leeuwarden, The Netherlands
M. Pijnenborg, N. Boonstra, A. Aleman

P-10-008
Comparing psychological interventions of different complexities with clinical outcomes in a high risk or psychotic adolescent sample
P. Palombi, Roma, Italy
A. Marconi, G. Colafrancesco, M. Ferrara

P-10-010
Competitive work and schizophrenia: design of a project aiming at obtaining and keeping a job through supported employment and multifacted collaboration
T. Kivekäs, Helsinki, Finland
K. Ahola, N. Nevala, K.-P. Martimo
P-11 POSTER SESSIONS

13.30 – 14.30 h  Foyer
Risk states
Chair:  A. Bechdolf, Berlin, Germany

P-11-001
Perception of neutral and negative stimuli in unaffected first-degree relatives of patients with schizophrenia
N. Klaasen, Groningen, The Netherlands
J. van der Velde, P. Gromann, M. Swart, E. Opmeer, D. Wiersma, R. Bruggeman, L. de Haan, L. Krabben-dam, A. Aleman

P-11-002
Emotion recognition as a predictor of transition to a psychotic disorder in ultra-high risk patients
M. Schaefer, Parkville, Australia

P-11-003
Mothers of schizophrenia patients: features of executive functions and face recognition
N. Khamenka, Minsk, Belarus
M. Skuhareuskaya

P-11-004
Social cognition, language and social functioning in children with genetic high risk for developing schizophrenia and bipolar disorder
C. J. Christiani, Copenhagen, Denmark

P-11-005
Neurocognitive profiles in 7-year-old offspring of parents with schizophrenia or with bipolar disorder – part of the Danish High Risk and Resilience Study „VIA 7”
N. Hemager, Copenhagen, Denmark

P-11-006
Psychopathology in offspring of parents with schizophrenia or bipolar disorder – Associations with neurodevelopmental disturbances and childhood stress. Part of the Danish high risk and resilience study – VIA 7
D. Ellersgaard, Copenhagen, Denmark

P-11-007
Maturation of mismatch negativity – implications for ultra high risk schizophrenia research
R. Thienel, Waratah, Australia

P-11-008
Comparison of two video-based assessments for abnormal motor behavior in adolescents at risk for psychosis
S. Schiebler, Bern, Switzerland
A. Tolev, K. Stegmayer, D. Hubl, W. Strik, F. Schultze-Lutter, B. Schimmelmann, S. Walther

P-11-009
Brain activation during self-reflection in ultra-high risk for psychosis
E. Opmeer, Groningen, The Netherlands
E. Liemburg, J. van der Velde, R. Nieboer, L. Wunderink, A. Aleman

P-11-010
Formal thought disorder in high-risk for psychosis individuals
M. Skuhareuskaya, Minsk, Belarus
Y. Fralova, N. Danilevich, E. Kudina

P-11-011
Neurocognition and catechol-O-methyltransferase Val/Met polymorphism in high-risk for psychosis individuals
M. Skuhareuskaya, Minsk, Belarus
V. Objedkov, I. Halayenka
P-11-012
Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: a comparison of prodromal psychotic symptoms and general functioning
M. Arzmando, Rome, Italy
S. Vicari, P. Girardi, D. Menghini, M. Digilio, M. Pontillo, R. Saba, L. Mazzone, A. Lin, M. Schafer, P. Amminger

P-12
POSTER SESSIONS
13.30 – 14.30 h
Foyer
Structural neuroimaging
Chair: A. Schmitt, Munich, Germany

P-12-001
White matter abnormalities in first episode psychosis: a DTI study
T. Melicher, Prague, Czech Republic
P. Mikolas, F. Spaniel, J. Horacek, P. Mohr

P-12-002
Processing speed impairment is related to white matter damage in schizophrenia
J. Pena, Bilbao, Spain
O. Rilo, N. Ibarretxe, O. Rusu, A. Loizaga, R. Avila, C. Schretlen, M. Varvaris, N. Ojeda

P-12-003
White matter pathways of the salience system are altered in schizophrenia
T. Bracht, Bern, Switzerland

P-12-004
Grey matter differences between bipolar patients and controls: a voxel-based morphometry meta-analysis
R. Ganzola, Quebec, Canada
S. Duchesne

P-12-005
Incidental radiological findings on brain magnetic resonance imaging in patients with first-episode psychosis and healthy controls
I. Falkenberg, Marburg, Germany
S. Benetti, W. Pettersson-Yeo, P. Dazzan, A. Simmons, S. Williams, P. McGuire

P-12-006
Structural alterations of the visual system in adolescents with first-admission schizophrenia
R. Henze, Heidelberg, Germany
R. Brunner, P. Parzer, M. Freitag, U. Thiemann, F. Resch, B. Stieltjes

P-12-007
Alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first episode of schizophrenic patients
E. Rizos, Athens, Greece
M. Papathanasiou, P. Michalopoulou, E. Laskos, A. Kastania, A. Douzenis, K. Vasilopoulou, I. Liappas

P-12-008
Proton MRS findings in the corpus callosum genu and auditory information processing in young male patients with schizophrenia
I. Lebedeva, Moscow, Russia
N. Semenova, S. Sidorin, V. Kaleda, A. Barkhatova, T. Akhadow
P-13 POSTER SESSIONS
13.30 – 14.30 h Foyer
Neuropsychology 3
Chair: P. Uhlhaas, Glasgow, United Kingdom

P-13-001
Spatial cognition in schizophrenia patients measured in virtual reality tests based on animal research
M. Rodriguez, Prague, Czech Republic
I. Fajnerova, K. Vlcek, C. Brom, L. Konradova, K. Dvořská, P. Mikolaš, D. Levcik, J. Horacek, A. Stuhlik

P-13-002
Mismatch negativity in birds
U. Schall, Callaghan, Australia
B. Müller, C. Kärgel, O. Güntürkün

P-13-003
Sensorimotor learning in stable schizophrenia patients compared to healthy young and elderly controls in two variations of the rotary pursuit
L. De Picker, Antwerp, Belgium
W. Hulstijn, G. Dumont, B. Sabbe

P-13-004
A study of Neurological Soft Signs (NSS) in schizophrenia
C. S. Gupta, New Delhi, India
T. Gupta, S. Pattanayak, S. Aggarwal

P-13-005
Predictive value of executive functions impairment in early-onset schizophrenia spectrum psychosis: 6 years follow-up study
B. Remberk, Warsaw, Poland
A. K. Bazynska, J. Bragoszewska, F. Rybakowski

P-13-007
Neurocognitive predictors of symptom severity in first-episode schizophrenia
C. Mohn, Drammen, Norway
A.-K. Torgalsbøen

P-13-008
Absorption and dissociative detachment, but not compartmentalisation, are associated with psychosis-like experiences in the general population
C. Humpston, London, United Kingdom
V. Bell, M. Mehta, Q. Deeley

P-13-009
Aberrant salience attribution in schizophrenia patients and healthy participants with delusional experiences
S. Diner, Berlin, Germany
A. Pankow, T. Katthagen, S. Koch, L. Deserno, A. Heinz, F. Schlagenhauf

P-13-010
Willed actions and mechanisms of initiation, production and control of cognitive responses in schizophrenia: a cue-based protocol
R. Rinaldi, Mons, Belarus
L. Lefebvre
### S-34 SYMPOSIA

**14.30 – 16.00 h Humboldt Hall**

**Obsessive-compulsive symptoms in schizophrenia**

*Chairs: M. Zink, Mannheim, Germany  
N. Fineberg, Hertfordshire, United Kingdom*

**S-34-001**

Obsessive compulsive symptoms in the early course of psychotic disorders  
*F. Schirmbeck, Mannheim, Germany*

**S-34-002**

Neurocognitive differences between schizophrenia patients with and without comorbid obsessive-compulsive symptoms  
*N. Fineberg, Hertfordshire, United Kingdom  
D. Patel, K. Mukhopadhaya, K. Laws*

**S-34-003**

Antiserotonergic antipsychotics such as clozapine induce or aggravate obsessive compulsive symptoms in schizophrenia  
*M. Zink, Mannheim, Germany*

**S-34-004**

Effectiveness and outcome predictors of cognitive-behavioral therapy for obsessive-compulsive disorder co-occurring with psychosis  
*A. Tundo, Rome, Italy  
L. Salvati, L. Cieri, M. Daniele, D. Di Spigno, R. Necci, A. Parena*

### S-35 SYMPOSIA

**14.30 – 16.00 h Kleist Hall**

**Psychological treatments for people with schizophrenia**

*Chairs: S. Ochoa, Sant Boi de Llobregat, Spain  
J. Usall, Sant Boi de Llobregat, Spain*

**S-35-001**

REPYFLEC cognitive remediation group training in schizophrenia – looking for an integrative approach  
*J. Usall, Sant Boi de Llobregat, Spain  
A. Farreny*

**S-35-002**

Metacognitive training in schizophrenia (MCT): immediate, delayed and „sleeper” effects  
*S. Moritz, Hamburg, Germany*

**S-35-003**

Cognitive-behavioral therapy for people with auditory hallucinations  
*E. Lorente, Valencia, Spain*

**S-35-004**

A randomized, controlled trial of neurocognitive training in schizophrenia  
*M. Linke, Warsaw, Poland  
M. Jarema, A. Wichniak, K. Jankowski*
### S-36 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 16.00 h</td>
<td>Loft A</td>
<td>Animal models of schizophrenia facing the complexity of genotype, environmental factors and phenotype</td>
<td>R. Wolf, Bochum, Germany, M. von Wilmsdorff, Düsseldorf, Germany</td>
</tr>
</tbody>
</table>

**S-36-001**

Differences in social behavior, prepulse inhibition, dopaminergic and serotonergic hippocampal fiber density of CPB-K mice compared to BALB/cJ mice  
P. Panther, Magdeburg, Germany  
S. Nullmeier, A. Kröber, S. Herbert, R. Wolf

**S-36-002**

Pre-treatment with the mGlu2/3 receptor agonist LY379268 attenuates DOI-induced impulsive responding, deficits in prepulse inhibition and regional c-Fos protein expression  
L. Wischhof, Bremen, Germany  
M. Koch

**S-36-003**

Disturbed gene expression caused by perinatal hypoxia in an animal model of schizophrenia  
A. Schmitt, Munich, Germany  
P. Gebicke-Härter, P. Falkai

**S-36-004**

Sex-dependent metabolic changes caused by drug treatment with haloperidol and clozapine in rats  
M. von Wilmsdorff, Düsseldorf, Germany

### O-07 ORAL PRESENTATIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 16.00 h</td>
<td>Einstein Hall</td>
<td>Structural neuroimaging</td>
<td>U. Schall, Callagahn, Australia</td>
</tr>
</tbody>
</table>

**O-07-001**

Factors associating to brain volume change in schizophrenia – the Northern Finland 1966 Birth Cohort  
S. Huhtaniska, Oulu, Finland  

**O-07-002**

Familial and unique environmental influences on brain volumes in twins with schizophrenia  
M. Picchioni, Northampton, United Kingdom  

**O-07-003**

Greater reductions in grey matter volume in a cognitive-deficit subtype of schizophrenia  
A. Shepherd, Darlinghurst, Sydney, Australia  
J. Wong, M. Dragovic, K. Laurens, A. Joblensky, V. Carr, M. Green

**O-07-004**

Supplementary motor area (SMA) volume correlates with psychotic symptoms associated with dysregulation of the motor system – A voxel-based morphometry (VBM) study  
K. Stegmayer, Bern, Switzerland  
H. Horn, A. Federspiel, N. Razavi, K. Laimböck, T. Bracht, W. Strik, T. Müller, R. Wiest, S. Walther

**O-07-005**

Relevance of posterior parietal areas for auditory verbal hallucination in schizophrenia: a voxel-based grey and white matter morphology study  
M.-J. van Tol, Gronningen, The Netherlands  
L. van der Meer, R. Bruggeman, G. Modinos, H. Knegtering, A. Alemán

**O-07-006**

Structural brain imaging correlates of At-Risk Mental State  
U. Schall, Callagahn, Australia  
T. Ehikes, P. Michie, R. Atkinson, P. Ward
URANIA, THIRD LEVEL
Lofts A, B and C with access via elevator on ground floor.

ACKNOWLEDGEMENTS

The organisers of the 4th European Conference on Schizophrenia Research (ECSR) gratefully acknowledge the support of:

Roche Pharma AG in terms of sponsoring (EUR 10,000)

German Research Association (DFG) in terms of an educational grant
INDEX OF CHAIRPERSONS, AUTHORS AND PRESENTERS

<p>| A    | Aas, M. ..............................................38 |
|      | Alesan, A. ...........................................15, 27 |
|      | Aliko, I. ..................................................18 |
|      | Allott, K. ..................................................45 |
|      | Amminger, G. P. .........................................36, 42 |
|      | Anderson, V. ...............................................31 |
|      | Andrade, G. ...............................................17, 28 |
|      | Armando, M. .............................................46 |
|      | Armijo, A. ..................................................16 |
|      | Arzberger, T. ...............................................39 |
|      | Awad, A. G. ..................................................37, 41 |
| B    | Balzan, R. ..................................................44 |
|      | Barajas, A. ..................................................30 |
|      | Barglow, J. ..................................................41 |
|      | Barachina, M. ...............................................21 |
|      | Bartsch, D. ..................................................25 |
|      | Bechdolf, A. ...........................................26, 36, 42, 45 |
|      | Bechter, K. ..................................................15 |
|      | Benítez-King, G. .........................................28 |
|      | Benson, P. ...................................................23 |
|      | Berg, A. .......................................................18 |
|      | Birchwood, M. ............................................36, 42 |
|      | Biter, M. ......................................................27 |
|      | Boeck, R. ......................................................29 |
|      | Bogojevic, G. ...............................................41 |
|      | Borgwardt, S. .............................................34, 40 |
|      | Borrocho-Escuella, D. ..................................15 |
|      | Bosco, F. M. ................................................44 |
|      | Boucart, M. ..................................................23 |
|      | Bracht, T. .....................................................46 |
|      | Brosda, J. .....................................................16 |
|      | Bugarski-Kirola, D. .....................................24 |
|      | Bull, H. .......................................................32 |
| C    | Capdevielle, D. ..........................................25 |
|      | Carpenter Jr., W. T. ....................................22 |
|      | Cheng, C. ....................................................30, 41 |
|      | Christiani, C. J. .........................................45 |
|      | Ciobanu, A. ...................................................19 |
|      | Cordes, J. .....................................................20 |
|      | Cuthbert, B. N. ...........................................14, 26 |
| D    | Daey-Ouwens, I. .......................................18, 28 |
|      | De Piker, L. ..................................................47 |
|      | De Santis, P. ................................................17 |
|      | Desero, L. ....................................................27, 29 |
|      | de Vos, A. .....................................................31 |
|      | Dierks, T. ......................................................43 |
|      | Diner, S. ......................................................47 |
|      | Dlabac-De Lange, J. .....................................15 |
|      | Dolz, M. .......................................................19 |
|      | Drusch, K. ....................................................17 |
|      | Duñó, R. .....................................................19 |
|      | E    | Eifler, S. ....................................................17, 25 |
|      | Ellersgaard, D. ...........................................45 |
|      | Engel, M. .....................................................17 |
|      | Englisch, S. ...............................................16 |
|      | Escartí-Fabra, M. J. .......................................30 |
|      | F    | Faerden, A. ....................................................15 |
|      | Falkai, P. ....................................................23, 27, 36 |
|      | Falkenberg, I. .............................................46 |
|      | Falkum, E. .....................................................39 |
|      | Farreyn, A. ....................................................48 |
|      | Fett, A.-K. ...................................................25 |
|      | Fineberg, N. ...............................................48 |
|      | Fischer, A. ....................................................27 |
|      | Fiste, M. .......................................................44 |
|      | Fleischhacker, W. ...........................................16, 20, 27 |
|      | Foucher, J. .....................................................38 |
|      | Foer, J. .........................................................29 |
|      | Friebe, A. .....................................................23 |
|      | Fukuda, Y. .....................................................29 |
|      | Fuser-Poli, P. .............................................20, 40 |
|      | Fuxe, K. .........................................................15 |
| G    | Gaebel, W. ...................................................14, 22, 24, 26, 36, 42 |
|      | Galderisi, S. .............................................14, 22, 24, 26, 36 |
|      | Gallinat, J. ...................................................43 |
|      | Ganzola, R. ....................................................46 |
|      | Garcia Mahia, M. Del Carmen ..................18, 31 |
|      | Gawlik, M. .....................................................38 |
|      | Gemma, E. .....................................................16 |
|      | Giakoumaki, S. ..............................................31 |
|      | Gleith, T. ......................................................28 |
|      | Gloria, M. .....................................................16 |
|      | Goel, D. .........................................................41 |
|      | Graikiotis, A. ..............................................16 |
|      | Grasa, E. .........................................................17 |
|      | Green, M. ......................................................17, 27 |
|      | Gromann, P. ....................................................29 |
|      | Gruber, O. .....................................................26 |
|      | Grünner, G. ....................................................26 |
|      | Gupta, C. S. ....................................................47 |
|      | Gutkevich, E. ................................................18 |
|      | H    | Hallaschek, J. ...............................................19 |
|      | Hasan, A. ......................................................27, 43 |
|      | Havemann-Reinecke, U. ..................................28 |
|      | Heinz, A. ......................................................14, 21, 29 |
|      | Heinze, M. ....................................................41 |
|      | Hemager, N. ....................................................45 |
|      | Henze, R. .....................................................46 |
|      | Hilker, R. .....................................................28 |
|      | Hodgkins, S. ................................................14, 20, 21, 37 |
|      | Horvat, B. .....................................................39 |
|      | Hosakova, K. ..................................................17 |
|      | Huerta-Ramos, E. .........................................31 |
|      | Huhtaniska, S. .............................................49 |
|      | Humpston, C. ..................................................47 |
|      | Husa, A. .........................................................24 |
| I    | Inta, D. .......................................................22 |
|      | Iritani, S. .....................................................28 |
|      | Islam, M. A. ...................................................37 |
|      | Isohanni, M. ...................................................24 |
|      | Jaeger, S. ......................................................32 |
|      | Jäger, M. .......................................................20 |
|      | Jarema, M. ......................................................32 |
|      | Javed, A. .......................................................42 |
|      | Joukamaa, M. ...................................................18 |
|      | Juckel, G. .......................................................23 |
|      | Jun, T.-Y. ......................................................16 |
|      | Kaiser, S. ......................................................15 |
|      | Käkelä, J. .....................................................39 |
|      | Kato, T. .........................................................35 |
|      | Katthagen, T. ..................................................29 |
|      | Kelleher, I. ....................................................20, 22 |
|      | Khamenka, N. ...................................................45 |
|      | Khan, M. F. .......................................................37 |
|      | Kircher, T. .....................................................21, 26 |
|      | Kivekäs, T. ......................................................44 |
|      | Klaesen, N. .....................................................45 |
|      | Klosterkötter, J. ..........................................20, 26, 40, 42 |
|      | Konstantinidis, A. .........................................20 |
|      | Kos, C. .........................................................32 |
|      | Koutsouleris, N. ..........................................34 |
|      | Krug, A. .........................................................26 |
|      | Kwon, J. S. ......................................................41 |
| L    | Lambert, M. ...................................................42 |
|      | Landgraf, S. ...................................................25 |
|      | Lang, F. .........................................................30 |
|      | Larach, V. W. ...............................................16, 19, 39, 42 |
|      | Lay, B. ...........................................................14 |
|      | Lebedeva, I. ....................................................46 |
|      | Lebedeva, V. ....................................................18 |
|      | Lennox, B. .......................................................15 |
|      | Li, C. .............................................................28 |
|      | Lincoln, T. .....................................................26, 44 |
|      | Linke, M. .......................................................48 |</p>
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mabry, A.</td>
<td>42</td>
</tr>
<tr>
<td>Lorente, E.</td>
<td>48</td>
</tr>
<tr>
<td>Luckhaus, C.</td>
<td>14</td>
</tr>
<tr>
<td>Lundt, A.</td>
<td>21</td>
</tr>
<tr>
<td>Lu, R.-B.</td>
<td>35</td>
</tr>
<tr>
<td>Lyrakos, G.</td>
<td>19</td>
</tr>
<tr>
<td>Lystad, J.</td>
<td>31</td>
</tr>
<tr>
<td>Mabry, A.</td>
<td>19</td>
</tr>
<tr>
<td>Macer, W.</td>
<td>25, 26, 36</td>
</tr>
<tr>
<td>Malda, A.</td>
<td>44</td>
</tr>
<tr>
<td>Marshall, M.</td>
<td>20</td>
</tr>
<tr>
<td>Martins-de-Souza, D.</td>
<td>39, 40</td>
</tr>
<tr>
<td>Mehl, S.</td>
<td>26</td>
</tr>
<tr>
<td>Melicher, T.</td>
<td>46</td>
</tr>
<tr>
<td>Melle, I.</td>
<td>34, 38</td>
</tr>
<tr>
<td>Miettunen, J.</td>
<td>24, 37</td>
</tr>
<tr>
<td>Mikhailova, I.</td>
<td>21</td>
</tr>
<tr>
<td>Miyakawa, T.</td>
<td>35</td>
</tr>
<tr>
<td>Mohn, C.</td>
<td>47</td>
</tr>
<tr>
<td>Müller, H.-J.</td>
<td>36</td>
</tr>
<tr>
<td>Mondelli, V.</td>
<td>22, 34, 38</td>
</tr>
<tr>
<td>Moritz, S.</td>
<td>48</td>
</tr>
<tr>
<td>Morrens, M.</td>
<td>43</td>
</tr>
<tr>
<td>Morton, S.</td>
<td>31</td>
</tr>
<tr>
<td>Mossaheb, N.</td>
<td>19</td>
</tr>
<tr>
<td>Mulert, C.</td>
<td>43</td>
</tr>
<tr>
<td>Müller, R.</td>
<td>41</td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>Neroutsos, E.</td>
<td>16, 30</td>
</tr>
<tr>
<td>Nielsen, M.</td>
<td>37</td>
</tr>
<tr>
<td>Nitschke, J.</td>
<td>14</td>
</tr>
<tr>
<td>Nordentoft, M.</td>
<td>34, 36</td>
</tr>
<tr>
<td>Nordholm, D.</td>
<td>22</td>
</tr>
<tr>
<td>Numagambetova, S.</td>
<td>30</td>
</tr>
<tr>
<td>O</td>
<td></td>
</tr>
<tr>
<td>Obeydov, V.</td>
<td>16</td>
</tr>
<tr>
<td>Ohlau, S.</td>
<td>30, 31, 48</td>
</tr>
<tr>
<td>Ohtsukani, M.</td>
<td>35</td>
</tr>
<tr>
<td>Oliveira, S.</td>
<td>39</td>
</tr>
<tr>
<td>Opmeer, E.</td>
<td>45</td>
</tr>
<tr>
<td>Orlava, V.</td>
<td>21</td>
</tr>
<tr>
<td>Østefjells, T.</td>
<td>17</td>
</tr>
<tr>
<td>Ovedo, G.</td>
<td>32</td>
</tr>
<tr>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Palombi, P.</td>
<td>44</td>
</tr>
<tr>
<td>Pankow, A.</td>
<td>29</td>
</tr>
<tr>
<td>Panther, P.</td>
<td>49</td>
</tr>
<tr>
<td>Papenasotropoulos, A.</td>
<td>21, 25</td>
</tr>
<tr>
<td>Pawlitzek, C.</td>
<td>37</td>
</tr>
<tr>
<td>Pena, J.</td>
<td>46</td>
</tr>
<tr>
<td>Penttilä, M.</td>
<td>24</td>
</tr>
<tr>
<td>Pfuhlmann, B.</td>
<td>38</td>
</tr>
<tr>
<td>Picchioni, M.</td>
<td>49</td>
</tr>
<tr>
<td>Pirlog, M. C.</td>
<td>32</td>
</tr>
<tr>
<td>Pratt, J. A.</td>
<td>25</td>
</tr>
<tr>
<td>R</td>
<td></td>
</tr>
<tr>
<td>Rausch, F.</td>
<td>27, 30</td>
</tr>
<tr>
<td>Rauschen, S.</td>
<td>35</td>
</tr>
<tr>
<td>Remberk, B.</td>
<td>47</td>
</tr>
<tr>
<td>Renard, S.</td>
<td>37</td>
</tr>
<tr>
<td>Reniers, R.</td>
<td>22</td>
</tr>
<tr>
<td>Rilo, O.</td>
<td>46</td>
</tr>
<tr>
<td>Rinaldi, R.</td>
<td>47</td>
</tr>
<tr>
<td>Rissanen, I.</td>
<td>32</td>
</tr>
<tr>
<td>Ritter, W.</td>
<td>17</td>
</tr>
<tr>
<td>Rizos, E.</td>
<td>46</td>
</tr>
<tr>
<td>Rodriguez, M.</td>
<td>47</td>
</tr>
<tr>
<td>Rojas Rivera, A. M.</td>
<td>44</td>
</tr>
<tr>
<td>Rössler, W.</td>
<td>36</td>
</tr>
<tr>
<td>Roux, P.</td>
<td>25</td>
</tr>
<tr>
<td>Ruhrmann, S.</td>
<td>20, 23, 34, 41, 42</td>
</tr>
<tr>
<td>S</td>
<td></td>
</tr>
<tr>
<td>Sadek, H.</td>
<td>18</td>
</tr>
<tr>
<td>Salokangas, R. K. R.</td>
<td>40</td>
</tr>
<tr>
<td>Sartorius, N.</td>
<td>24, 37, 42</td>
</tr>
<tr>
<td>Schaefer, M.</td>
<td>45</td>
</tr>
<tr>
<td>Schall, U.</td>
<td>27, 47, 49</td>
</tr>
<tr>
<td>Schiebler, S.</td>
<td>45</td>
</tr>
<tr>
<td>Schiffer, B.</td>
<td>37</td>
</tr>
<tr>
<td>Schirmbeck, F.</td>
<td>29, 37, 48</td>
</tr>
<tr>
<td>Schlaglaufer, F.</td>
<td>29</td>
</tr>
<tr>
<td>Schmidtke, A.</td>
<td>22</td>
</tr>
<tr>
<td>Schmidt-Kraepelin, C.</td>
<td>20</td>
</tr>
<tr>
<td>Schmitt, A.</td>
<td>23, 39, 46, 49</td>
</tr>
<tr>
<td>Schröder, J.</td>
<td>43</td>
</tr>
<tr>
<td>Schulze, T.</td>
<td>25, 28</td>
</tr>
<tr>
<td>Shepherd, A.</td>
<td>49</td>
</tr>
<tr>
<td>Shklover, V.</td>
<td>21</td>
</tr>
<tr>
<td>Sigurdsson, T.</td>
<td>41</td>
</tr>
<tr>
<td>Simpson, S.</td>
<td>31</td>
</tr>
<tr>
<td>Skhureuskaya, M.</td>
<td>45</td>
</tr>
<tr>
<td>Spinaris, V.</td>
<td>19</td>
</tr>
<tr>
<td>Stegmayr, K.</td>
<td>49</td>
</tr>
<tr>
<td>Steiner, J.</td>
<td>23, 39, 40</td>
</tr>
<tr>
<td>Sterzer, P.</td>
<td>35, 37</td>
</tr>
<tr>
<td>Stöber, G.</td>
<td>38</td>
</tr>
<tr>
<td>Strick, W.</td>
<td>14, 18, 21, 26</td>
</tr>
<tr>
<td>Stroth, S.</td>
<td>23</td>
</tr>
<tr>
<td>T</td>
<td></td>
</tr>
<tr>
<td>Takal, A.</td>
<td>44</td>
</tr>
<tr>
<td>Tanra, A. J.</td>
<td>35</td>
</tr>
<tr>
<td>Tarrago, J.</td>
<td>27</td>
</tr>
<tr>
<td>Terock, J.</td>
<td>35</td>
</tr>
<tr>
<td>Tesse, M.</td>
<td>31</td>
</tr>
<tr>
<td>Thienel, R.</td>
<td>45</td>
</tr>
<tr>
<td>Thorup, A.</td>
<td>39</td>
</tr>
<tr>
<td>Tolley, C.</td>
<td>30</td>
</tr>
<tr>
<td>Trauelsen, A. M.</td>
<td>38</td>
</tr>
<tr>
<td>Tundo, A.</td>
<td>48</td>
</tr>
<tr>
<td>U</td>
<td></td>
</tr>
<tr>
<td>Uhlhus, P.</td>
<td>35, 41, 47</td>
</tr>
<tr>
<td>Urano, N.</td>
<td>40</td>
</tr>
<tr>
<td>Usall, J.</td>
<td>32, 48</td>
</tr>
<tr>
<td>Uzay, T.</td>
<td>21</td>
</tr>
<tr>
<td>V</td>
<td></td>
</tr>
<tr>
<td>van Harten, P. N.</td>
<td>43</td>
</tr>
<tr>
<td>van Tol, M.-J.</td>
<td>49</td>
</tr>
<tr>
<td>Verhooven, W.</td>
<td>28, 38</td>
</tr>
<tr>
<td>von Wilsdomm, M.</td>
<td>49</td>
</tr>
<tr>
<td>Voss, M.</td>
<td>35</td>
</tr>
<tr>
<td>W</td>
<td></td>
</tr>
<tr>
<td>Walter, H.</td>
<td>27</td>
</tr>
<tr>
<td>Waldner, S.</td>
<td>21, 43</td>
</tr>
<tr>
<td>Ward, P.</td>
<td>31, 41</td>
</tr>
<tr>
<td>Wasserman, D.</td>
<td>22</td>
</tr>
<tr>
<td>Weidinger, E.</td>
<td>15</td>
</tr>
<tr>
<td>Werscholb, L.</td>
<td>49</td>
</tr>
<tr>
<td>Wolf, R.</td>
<td>49</td>
</tr>
<tr>
<td>Wolf, S.</td>
<td>23</td>
</tr>
<tr>
<td>Wöllner, W.</td>
<td>23, 25</td>
</tr>
<tr>
<td>Wood, S.</td>
<td>22, 34</td>
</tr>
<tr>
<td>Wright, B.</td>
<td>25, 31</td>
</tr>
<tr>
<td>Wulff, S.</td>
<td>29</td>
</tr>
<tr>
<td>Wunderink, L.</td>
<td>34</td>
</tr>
<tr>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Xia, L.</td>
<td>40</td>
</tr>
<tr>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Yao, J.</td>
<td>21</td>
</tr>
<tr>
<td>Yung, A.</td>
<td>40</td>
</tr>
<tr>
<td>Z</td>
<td></td>
</tr>
<tr>
<td>Zilles, K.</td>
<td>26</td>
</tr>
<tr>
<td>Zink, M.</td>
<td>48</td>
</tr>
<tr>
<td>Zuleta, P.</td>
<td>18</td>
</tr>
</tbody>
</table>
SAVE TIME AND LET THE RESEARCH COME TO YOU
SIGN UP FOR TABLE OF CONTENTS ALERTS FROM
ACTA PSYCHIATRICA SCANDINAVICA

Editor-in-Chief: Povl Munk-Jørgensen, Copenhagen, Denmark

Acta Psychiatrica Scandinavica acts as an international forum for the dissemination of information advancing the science and practice of psychiatry. In particular we focus on ‘translating’ frontline research into useful updating information for the benefit of clinical psychiatry and clinical psychiatric research.

About Table of Contents Alerts from Acta Psychiatrica Scandinavica

Table of Content Alerts are the fastest and easiest way to get to main points of new research. When a new Acta Psychiatrica Scandinavica issue publishes you’ll receive an email notification automatically that features the latest table of contents with links to article abstracts. If your institution subscribes you will be able to access the full-text version of each article.

Best of all, your e-alert registration is available at no cost and completely risk-free. You can opt-out at any time, for any reason – no questions asked. Subscribe for free today!